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WITNESS SEMINARS:
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine
Group, as part of the Academic Unit of the Wellcome Institute for the History
of Medicine, to bring together clinicians, scientists, historians and others
interested in contemporary medical history. Among a number of other
initiatives the format of Witness Seminars, used by the Institute of
Contemporary British History to address issues of recent political history, was
adopted, to promote interaction between these different groups, to emphasize
the potential benefits of working jointly, and to encourage the creation and
deposit of archival sources for present and future use. In June 1999 the
Governors of the Wellcome Trust decided that it would be appropriate for the
Academic Unit to enjoy a more formal academic affiliation and turned the
Unit into the Wellcome Trust Centre for the History of Medicine at University
College London from 1 October 2000. The Wellcome Trust continues to fund
the Witness Seminar programme via its support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several
people associated with a particular set of circumstances or events are invited to
come together to discuss, debate, and agree or disagree about their memories. To
date, the History of Twentieth Century Medicine Group has held nearly 40 such
meetings, most of which have been published, as listed on pages xi–xviii.
Subjects are usually proposed by, or through, members of the Programme
Committee of the Group, and once an appropriate topic has been agreed,
suitable participants are identified and invited. This inevitably leads to further
contacts, and more suggestions of people to invite. As the organization of the
meeting progresses, a flexible outline plan for the meeting is devised, usually
with assistance from the meeting’s chairman, and some participants are invited
to ‘set the ball rolling’ on particular themes, by speaking for a short period to
initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited
transcript is immediately sent to every participant. Each is asked to check his
or her own contributions and to provide brief biographical details. The editors
turn the transcript into readable text, and participants’ minor corrections and
comments are incorporated into that text, while biographical and
bibliographical details are added as footnotes, as are more substantial
comments and additional material provided by participants. The final scripts
are then sent to every contributor, accompanied by forms assigning copyright
to the Wellcome Trust. Copies of all additional correspondence received
during the editorial process are deposited with the records of each meeting in
Archives and Manuscripts, Wellcome Library, London.
As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the non-specialist, the sense and significance
of the events will be understandable. Our aim is for the volumes that emerge
from these meetings to inform those with a general interest in the history of
modern medicine and medical science; to provide historians with new insights,
fresh material for study, and further themes for research; and to emphasize to
the participants that events of the recent past, of their own working lives, are
of proper and necessary concern to historians.
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INTRODUCTION
It is a great privilege to have been asked to provide an introduction to this
important and interesting Witness Seminar on innovation in pain
management. In 1999 I spent a three-month sabbatical, awarded by the
Wellcome Trust, at the Wellcome Institute for the History of Medicine [the
forerunner of the Wellcome Trust’s Centre for the History of Medicine,
UCL]. My focus was to explore the influence of the discovery of the opioid
receptors on the management of cancer-related pain.1,2 I entered the work
from a biomedical perspective and was soon immersed additionally in a world
of beliefs and myths, psychology and the influence of personality, spirituality
and religion, politics and law. I am delighted that this witness seminar has
brought out flavours of all of these aspects of pain and its management and,
indeed, has been honest enough to mention others such as human and
corporate greed.
Pain management in the second half of the twentieth century was influenced,
of course, by a wide variety of factors. Opium3 had been utilized for pain relief
for centuries and in 1805 morphine was isolated.4 Salicylate as an anodyne (in
the form of willow bark)5 had been known about for nearly 300 years and its
synthesized form was launched as aspirin by Bayer in 1899.6 Bayer had just
put diamorphine, its ‘heroic’ drug, on the market, thought to be superior to
morphine, in that it was more effective, non-sedating and non-addictive.7
Addiction was an ever-present issue. The invention of the hypodermic syringe
in the mid-nineteenth century was in large part targeted at effective
administration of narcotics, with the suggestion that this might avoid
addiction. Florence Nightingale remarked:
1 Faull and Nicholson (2003).
2 Faull (1999). 
3 Booth (1996).
4 Huxtable and Schwarz (2001).
5 Weatherall (1993).
6 See www.aspirin.com/world_of_aspirin_en.html (visited 3 June 2004).
7 Daly (1900).
Nothing did me any good but a curious little new-fangled
operation of putting opium under the skin which relieved one for
24 hours.8
However, addictive behaviour could not be avoided by this route of
administration of narcotics, which lead to the coining of the word
‘morphinism’ for this new form of intoxication.9 By the mid-1950s
diamorphine had proved that it too could lead to addiction and there was great
international debate about its continued medicinal use.10
Alongside these factors, Roselyne Rey discusses the innovations in science and
explorations of anatomy and physiology in the nineteenth century, the
tensions between the anatomical and physiological, the mental and the moral
experiences of pain and the evolution of the conceptualization of pain within
the framework of specificity theory.11 The specificity theory dominated the
approach to medicine in general, and pain in particular at the beginning of the
twentieth century. By the 1940s this approach to pain was beginning to be
challenged on the basis of both laboratory and clinical evidence. Sir Thomas
Lewis’s Pain was key in providing a rigorous exploration of clinical
observations and experiments in pain in human beings.12 The American
surgeon William Livingston, in Pain Mechanisms13 and the posthumously
published Pain and Suffering,14 subjected such evidence and the predominant
framework for the understanding of pain, to clinical observational critique. He
found that the experiences of his patients with nerve injury did not fit well
with the specificity theory and he looked for other frameworks for pain,
exploring concepts of neuromodulation, inhibition and gating, and temporal,
spatial and summation patterning of stimuli. He was key to the field of pain
research, theory and clinical practice that suddenly came alive in the second
half of the twentieth century. 
xx
8 Porter (1997): 663. Florence Nightingale was bedridden for much of her adult life. Brucellosis has
recently been proposed as the cause, see McDonald (ed.) (2001), 33–60.
9 Arnold et al. (organizers) (1998).
10 Faull and Nicholson (2003). Virginia Berridge has written extensively on opium use and
addiction. See, for example, Berridge (1982).
11 Rey (1995).
12 Lewis (1942).
13 Livingston (1943).
14 Livingston (1998).
It is perhaps worthy of note that in the USA, innovations in pain in the 1940s
and 1950s were fuelled by the work of clinicians with injured veterans of the
war, especially the experiences of phantom limb pain and causalgia. Most
notable of these were William Livingston and anaesthetists Henry Beecher and
John Bonica.15 In the UK, the stimulus to innovation in pain management has
to a large extent been the plight of people with cancer.16 As Dr Marcia
Meldrum identifies in her overview to the Witness Seminar (pages 3–5), what
united these people, with different backgrounds, different patient groups and
different approaches, was a recognition that pain was more than a
somatosensory phenomenon. The witness seminar takes the story on from this
point in time. 
The seminar explores evidence about innovations in the treatment of both
cancer- and non-cancer-related pain – the use of drugs, cognitive behavioural
approaches and nerve blockage. It also looks at global public health
innovations in relation to cancer pain management, specifically the
development and implementation of the WHO analgesic ladder and the
worldwide use of morphine. It is an eclectic range and mix of evidence and
oral history. 
For me, some points of fascinating commonality emerge. The first is the role
of serendipity in the development of innovation. For example, when Cicely
Saunders  went to work as a nurse at St Luke’s Home for the Dying Poor, she
noticed that the nurses ignored the prescription instruction of ‘PRN’17 and
were administering morphine four-hourly, regularly.18 This lack of compliance
with or misinterpretation of doctors’ instructions provoked the most
important innovation in cancer pain management. When Cicely had her first
major opportunity to share this innovation she had investigated the regular
giving of morphine with more than 900 patients.19 Another example,
humorously portrayed by psychologist Chris Main, who coincidently worked
xxi
15 Baszanger (1998). See www.library.ucla.edu/libraries/biomed/his/bonica/index.html (visited 
2 June 2004). 
16 Saunders’ personal experiences were her major drive, but perhaps two key reports contributed to
more global endorsement and provided the fertile ground for the hospice movement to grow,
including the provision of research funds for pain research. See Joint National Cancer Survey
Committee (1952); Glyn Hughes (1960); Clark (1999).
17 See note 11, on page 6.
18 Dame Cicely Saunders, pages 6–7. RSM (1963).
19 Saunders (1963).
just down the corridor from orthopaedic surgeon Gordon Waddell, is the
serendipitous failure of Main’s initial research project, which lead to a highly
creative innovation in pain management programmes in chronic back pain.20
Secondly, there are the examples scattered throughout the seminar of attitudes to
pain and its management by the seminar participants’ professional colleagues: 
It was a matter of patients being rendered so that they didn’t
know what they were doing, by doctors who certainly didn’t
know what they were doing.21
You can’t control pain without killing the patient.22
Despite…awareness of palliative care…staff had very low
expectations of what could be achieved in their own area of
care...there was neither the knowledge nor the vigour to address
the problem.23
I enquired why narcotics were not available to men and was told
that men don’t need powerful drugs like that.24
I could smell the fear of addiction in America.25
Medical textbooks and papers in the 1960s and 1970s additionally convey the
enormous extent of misperceptions about pain and fear of narcotic analgesics.26
The third point is the oft-repeated statement that pain is a sensory and
emotional experience. Despite the audience being in full agreement, there is
still a clear challenge to the perspectives that each disciplinary branch has
taken. For example, Saunders refers to her anaesthetist colleagues as ‘blockers’
and this is mildly rebuffed by Jan Stjernswärd.27 Although they were using this
term in two different senses, the interchange seems to me to be revealing. Main
xxii
20 Professor Main, page 31.
21 Professor Vere, page 15.
22 Professor Vere, page 15.
23 Mrs Raiman, page 18.
24 Professor Bond, page 21.
25 Mr Joranson quoting Dr Twycross, page 49.
26 See Faull and Nicholson (2003); Faull (2000).
27 Dame Cicely Saunders, page 11, and Professor Stjernswärd, page 43, who refers to a person who
inhibits progress.
indicates his concern that the cancer pain management movement has paid
little attention to integration of the science and techniques of cognitive
behavioural approaches to pain, using instead a predominantly pharmaceutical
approach.28 On several occasions David Clark endeavoured to deepen
discussion about connectivity and division between the parallel worlds.29
Fourthly, consider the insight into the manner in which individuals played their
roles in the achievement of innovation. Obviously there is the factual report of
what happened, but the personal style of operation is also revealed to some extent.
For example, Robert Twycross (page 26) ensures that he gets across points he
thinks are of particular importance even if unrelated to the question the question
under discussion; Main recounts very colourful and reflective pictures of how
things came about;30 Saunders and Jennifer Raiman relate their thoughts to the
patients’ experiences;31 Saunders’ innovations have been enabled by social contacts
and other networking;32 Sir Michael Bond has followed a path dictated by his
health;33 Mark Swerdlow, David Joranson and Stjernswärd have worked to bring
people together to improve  effectiveness and dissemination of innovation.34
The interrelationships, the geneology of innovations in pain management, if
you like, between the witnesses and others involved is fascinating – who
worked with whom; who met whom where and the impact it had. Small world
networks is a modern science, but one that has greatly influenced the
development of the world of pain management. One example is the battle,35
briefly alluded to in the seminar, between the UK and the USA with respect to
the evidence that morphine given orally was effective: 
They were all certainly very polite to me but I think they were 
fairly unconvinced.36
xxiii
28 Professor Main, pages 1, 34–35.
29 Professor Clark, page 11 and page 34.
30 See page 31.
31 See pages 6 and 18.
32 A further exploration of this theme can be found in Clark (1998).
33 See page 11.
34 See, for example, pages 10, 39–48 and 52–59.
35 This is discussed in more depth in Faull and Nicholson (2003) and Meldrum (2003a). 
36 Dame Cicely Saunders, page 7.
As Meldrum’s overview identified the coming together of those working in the
pain field did far more than reduce the sense of isolation for practitioners. The
growing understanding of all involved of the complexity of pain demanded
integrated research and practice from a range of specialities. It was upon this
basis that Wall and Bonica founded the International Association for the Study
of Pain in 1973 and the multiprofessional journal Pain in 1976.37
Of course, the seminar is not comprehensive in its discussion of pain
innovations in this period, nor in the witnesses that were present. One facet
that is particularly underexplored is that of the neurosciences. The lack of
exploration of the innovations in models of pain and analgesia, the placebo
response, the identification of opioid and other receptors and ligands and
neuromodulatory techniques, such as transcutaneous nerve and dorsal column
stimulation and acupuncture, leave a notable gap. This can be usefully
investigated separately, but I think it its absence indicates what little influence
that laboratory innovation has had on clinical innovation. For instance the
celebrated discovery of the endogenous opioid receptors and ligands38 had
resoundingly little impact on clinicians at the time, nor has it lead to
innovation in pain management in the subsequent 25 years.39 Or is it that it is
too subtle to be overtly recognized? A clear example of how neuroscience has
directly influenced pain management is in spinal analgesia where, subsequent
to the discovery of opioid receptors in the spinal cord, the spinal infusion
incorporated opioid drugs in addition to the traditional local anaesthetic.40
The gate theory of pain41 and the enormous body of work of Patrick Wall
influenced and challenged both professional and public understanding of the
physical and somatosensory experience of pain, and this is mentioned in this
seminar (pages 23, 37 and 68) and an informative interview with Wall is
attached as Appendix 1. However, exploitation of the context and impact is
not detailed in a way that usefully explores its historical positioning in
influencing innovation in pain management from the breadth of perspectives
of the witnesses.
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It is my hope that this introduction will excite readers to learn more about
development and change in pain management through the format of oral
history and debate among key players in that history. An unexpected gain for
me was that the seminar made me laugh out loud at more than one point!
Professor Main’s statement that psychologists would rather use each other’s
toothbrushes than each other’s questionnaires42 helps me to understand my
colleagues and their culture just a little, but more important, to reflect on the
complexity of developing an effective evidence base and tool kit that is most
helpful for clinicians and patients.
Christina Faull
Consultant in Palliative Medicine, Leicestershire and Rutland Hospice and
University Hospitals of Leicester.
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Professor David Clark: It’s a great pleasure to be here as your Chair for the
afternoon. Like many of you, I have not been to one of these events before and I
think we are all coming to it with a little trepidation. I am going to first of all invite
Dr Marcia Meldrum, who is a historian of medicine at the University of California,
Los Angeles (UCLA), to start the afternoon off for us with a brief overview of the
entire field that we then hope to explore in more detail as the discussion progresses. 
Dr Marcia Meldrum: Thank you, David. Well, I think the one thing we need
to start off by saying is that, indeed, physicians didn’t start working to relieve
and manage pain in 1945, but that they have always done so. But in the late
1940s and the 1950s, there was a group of innovators in several specialities and
several different countries, who redefined pain in the clinical setting, as more
than a somatosensory phenomenon, more than a symptom of underlying
disease. And with their recognition that human pain had to be understood in
the individual patient, with all the complexity of factors that entailed, they laid
the groundwork for our present understanding. Just to mention a few of these,
all these names are well known to you, I am sure: Henry Beecher1 and John
Bonica2 in the US, Cicely Saunders and Mark Swerdlow in the UK, Willem
Noordenbos in the Netherlands, Paolo Procacci in Italy.
Initially I think, and particularly for the individuals themselves, it seemed as if
they were isolated voices in the wilderness, but over time people began to learn
of each other’s work, they began to write to each other and to visit. I believe
the first formal organization of clinicians interested in pain was brought
together in 1967 here in the UK by Dr Mark Swerdlow.3 As I am sure you all
know, John Bonica had the vision of an interdisciplinary pain organization to
bring together scientists and physicians. The necessity of such a group
appeared to him to be two fold. First, that pain was so complex a
phenomenon, involving the patient’s sensory, cognitive, affective, and
behavioural systems that demanded research from virtually every speciality,
and certainly from both basic researchers and clinical researchers, utilizing
both types of skills and expertise.
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But second, pain seemed, at this point in the early 1950s when Bonica began
his work, so neglected and marginalized as a problem within medicine, that he
saw it as a political necessity to build a critical mass with the collaboration of
workers from many fields. It was also part of Bonica’s vision that this be an
international field, and he worked consistently not only in the US, his adopted
country, but also in Italy (which was his homeland), as well as contacting and
working with other clinicians and scientists around the world. In the late
1960s, I think, he formed probably his most crucial alliance with the British
physiologist Patrick Wall, who is also, I think, known to everyone here.
As you probably know, the founding meeting of the International Association
for the Study of Pain (IASP) took place in May 1973, in the small community
of Issaquah, near Bonica’s hometown, Seattle, Washington. But you may not
know that there was a series of meetings leading up to this where Bonica met
with colleagues in a number of countries; and probably the most crucial of these
took place in April 1973, only a month before Issaquah, at a meeting organized
by Dr Wall in Jerusalem. It was called the Bat-Sheva Seminar on Pain
Mechanisms and Therapy. And John Bonica, Ronald Melzack, and Willem
Noordenbos all travelled to Israel for that meeting, as did Harold Merskey. In
the correspondence4 planning that trip, we also see Wall and Bonica planning
their strategy for the foundation of the IASP at the Issaquah meeting to follow
a month later.
There seem to have been three main trends or developments in pain relief. In
the 1950s Bonica and a number of colleagues would refine the techniques of
the anaesthetic block, originally introduced by René Leriche in the First World
War,5 a less drastic alternative to neurosurgery, but the principle was the same,
to disable the sensory pathways and prevent pain information from reaching
the brain. In the 1960s a number of psychologists and psychiatrists – here I
only mention a couple of names, Bill (Wilbert) Fordyce at the University of
Washington and Richard Sternbach in San Diego – began to develop
behavioural methods of pain management, ways to try to utilize the body’s
own, the mind’s own defence mechanisms to help manage pain and to help the
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patient to function effectively despite his pain.6 But the chief hope of patients
and clinicians remained a better analgesic, a drug that would free the patient
from subjection to pain, without altering his life.
At the start of this period in the late 1940s there was much hope placed on the
development of a non-narcotic analgesic, a variant of the morphine molecule
which would control pain without its well-known gastro-intestinal, respiratory
and cognitive effects.7 Many, many such compounds were isolated and tested,
but by the 1970s, however, it became clear that none of the new drugs was
superior to morphine, and that quite a few were indeed worse; and as a number
of people in this room have shown, what was needed was not to replace
morphine, but to come to know it much better and more intimately than we
had.8 And although there are a number of new pharmaceuticals, we haven’t
solved the problem of pain for all patients, but today at least we hope to learn
more about how much has been done in the last 50 years.
Clark: I am going to invite Dame Cicely Saunders to begin the discussion and
perhaps with a reminder of that famous phrase, ‘There’s so much more to be
learned about pain’.9
Dame Cicely Saunders: I am very honoured to start and, of course, I must
begin by saluting John Bonica, whose ground-breaking, multiprofessional
approach really goes back to 1947, according to his obituary,10 when he
involved a nurse and a neurosurgeon to join his team in Washington state. And
his career after that is an epic. I expect we will hear more about his books, his
lectures, his conferences and everything else. But it is a wonderful story. 
At about the same time, in March 1948, I was impelled by the stories of my
patients that I had experienced first as a nurse, but most of all as a social
worker. I knew I had to do something about end-of-life pain and I went, as a
State Registered Nurse (SRN) volunteer, to one of the early homes. There I
found that the nurses seeing the prescriptions of morphine four-hourly
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‘PRN’11 by the doctors, quite quietly took ‘PRN’ off and gave the drug four-
hourly, so as to prevent pain ever happening. This regular oral four-hourly
giving of morphine dates back to 1935, fairly soon after the Brompton cocktail
was put together.12
Now I was very impressed by this, because the patients were so much better
with the pain control than the ones I had seen in hospital before then. During
that time I took Mr Norman Barrett, the surgeon I was working for, to see this,
and to visit a patient at home and so on. When I said to him, ‘I am going to
have to go back and nurse the dying somehow,’ he said, ‘Go and read medicine.
So many doctors desert the dying, and there’s so much more to be learnt about
pain, and you will only be frustrated if you don’t do it properly, and they won’t
listen to you.’13 So I did read medicine and eventually arrived in 1958 at St
Mary’s Hospital Medical School in the department of pharmacology under
Professor Harold Stewart, who had found a grant for me to look at St Joseph’s
Hospice on the nature and management of terminal pain.14
Going there, which was virtually untouched by medical advance, I was able to
introduce records and the regular giving [of morphine] which they hadn’t
started, and according to one of the sisters of the ward that I was first in, it was
the change from painful to pain-free. Having been given four patients to look
after, I was soon looking after every admission into those 45 beds. So I began
keeping records in detail, pre-computer, on a punch card system, and making
tape recordings of patients talking about their pain from 1960, and I realized
that what we were looking at was what I described later, in 1964, as total
pain.15 And I will quote from one patient, when I said to her, ‘Tell me about
your pain, Mrs H.’ She just said, 
Well, doctor, it began in my back, but now it seems that all of me
is wrong. I could have cried for the pills and the injections, but I
knew that I mustn’t. Nobody seemed to understand how I felt, and
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it seemed as if the whole world was against me. My husband and
son were marvellous, but they would have to stay off work and lose
their money, but it’s so wonderful to begin to feel safe again. 
And so she has really talked about the physical, the psychological, the social,
and her spiritual need for security to look at who she was, coming to the end
of her life. And for another patient it was, ‘All pain and now it’s gone, and I
am free’. 
So I spent a lot of time in the Royal Society of Medicine library, looking up
everything I could find about pain, and found one of the very important
books, by F J J Buytendijk, a Professor of Psychology from the Netherlands on
pain,16 but very little in the textbooks, as Bonica has frequently told us,17
nothing except for anecdotes about avoiding strong drugs as long as you can,
and the problems of tolerance and addiction. But I knew from the work that
we were doing that that need not be a clinical problem, and when I presented
this in a paper to the Royal Society of Medicine (RSM) in 1962, I had 900
patients that I could refer to and talk about the doses that they had taken and
shown no tolerance, no drug dependence, alert and cheerful patients, and I
quote from what was in the Proceedings the next year: ‘It is not possible to treat
pain in isolation. We have to consider the whole person’.18 I could state very
firmly that oral morphine works, that is if it is given regularly, balance the need
and with the many adjuvants that came on board during the 1950s. 
And after this I went over to the US in 1963 and met Dr Beecher, Dr Lasagna,
and Houde and Wallenstein who were doing their own clinical trials, but
mainly by injection and mainly single-dose studies,19 and also in Boston I met
D E Weissman who was looking at end-of-life psychological pain. They were
all certainly very polite to me, but I think they were fairly unconvinced. But as
Patrick Wall wrote in 1986, 
The old methods of care and caring had to be rediscovered and
the best of modern medicine had to be turned to the task of new
study and therapy specifically directed at pain.20
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And I was very glad to have links with him from the 1970s. He spent five days
going round our wards, as if it were bird-watching. It was absolutely
fascinating to see how he spotted the one patient who had the chronic pain
syndrome and how different he was from nearly everybody else. But he was
certainly another giant figure.21
In 1967 St Christopher’s Hospice was opened in Sydenham, London, as the
first research and teaching hospice. Later we welcomed Robert Twycross, and
I had a grant waiting from the Department of Health and Social Security
(DHSS) to compare morphine and diamorphine. Robert [Twycross] came to
us in 1970 and did the extensive trials in great detail,22 which I hope he will be
able to talk about later, and reaffirmed that tolerance and addiction were
simply not clinical problems with practically every patient. But I did know that
your enthusiasms have to be tested and also that we were getting better at
everything so that the controls with in-patient study were really important,
because you were then able to say, ‘It’s not the drug that you use, it’s the way
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Figure 1: Dr Cicely Saunders and two patients at St Joseph’s on their golden
wedding anniversary, 1960.
that you use it that really matters’. And my aim had been to establish a simple
transferable regime that could be translated with well-known drugs across the
world, and used with the simplicity which we had shown can be handed on,
and this was of course picked up by the World Health Organization (WHO),
which I am sure we will hear about later.23
But I have to say that this crusade is simply not over. The drugs are withheld
and other manoeuvres are not always considered and, as Patrick Wall wrote in
his introduction to the fourth edition of the Textbook of Pain, ‘Pain, for me,
arrives as a complete package,’24 and that demands a team approach. Bonica
pioneered it, and I did write to him in 1966, which was when I first got in
touch, saying that I wanted to learn more about what he was doing. But we
both wanted what we knew to be made available to everybody in need. There
is plenty still to do. I would like to finish by saluting Peter Nathan, who died
last week and whom I tracked down and who in 1952 had an article in the
British Medical Journal, which I have dug out of my records.25 He showed that
most patients with severe pain can take large amounts of these drugs without
becoming addicts, and if their pain is relieved surgically, they will not ask for
these analgesic drugs. And pain can be relieved not just surgically, but by a
whole-team approach and by listening to their story. ‘It was all pain, but now
it has gone’ is one of the best things you can hear.
Clark: Peter Nathan sadly had given his apologies for this meeting and, as we
have heard, died just last week. Could I ask Dr Mark Swerdlow to continue on
from there, with some reflections from around that same period, in the late
1960s in particular. 
Dr Mark Swerdlow: If I may go back a bit further to 1884 when Carl Koller
demonstrated that injecting cocaine would produce local anaesthesia. For a
patient with severe pain to have an injection and for the pain to magically
disappear is such a conjuring trick, except of course that in no time at all the
pain was back, because local anaesthetics don’t last very long. So we then move
on to 1901 when Rudolf Schlosser injected alcohol on to nerves and that gave
a rather more lasting relief. Following from that surgeons, particularly in
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Germany and the US, set up clinics where they injected alcohol on to nerves
to relieve pain. For quite a little while they were busy doing that, until they
found that there were all sorts of surgical operations that were far more
interesting and remunerative and they gave up that practice. Anaesthetists
became the ones who injected solutions on to nerves for pain relief. 
But it’s not surprising, then, that in the US in 1936 Emery Rovenstine opened
the first pain clinic ever and this was purely a nerve block clinic.26 In 1948 John
Bonica opened one and quite a few other anaesthetists in America opened this
style of pain-relief clinic. Now because of the Second World War, the idea of a
pain-relief clinic [was widespread] and most of us used the principle of it,
[although its practice] didn’t spread outside the US; in fact, you might be
interested to know that in 1947 the first pain clinic in Europe was opened here
in London at University College Hospital (UCH). Later, a few more were
opened in various parts of England. 
In 1954 I had a year’s experience of this new phenomenon in a pain clinic in
Pennsylvania. I found it quite fascinating and went back home to England and
opened my own pain clinic as a regular session in 1959. There were quite a few
clinics opened here and there in England, and by 1960 I wished that there was
some way in which one could meet colleagues and discover what they were
doing, what sort of complications they were getting, what sort of patients they
were treating in their pain clinics, to get some joint information going. 
So in 1967 I invited everyone I knew in the pain field in England – there were
29 pain clinics in all – to the University of Manchester at Salford Hospital to
a discussion meeting. Seventeen of the 29 actually came and we had a splendid
day’s discussion which everyone thoroughly enjoyed and, I think, benefited
from. At the end of the day they unanimously voted that we should repeat this
process the following year and in fact each year thereafter, and that was the
start of the Intractable Pain Society of Great Britain. At first it was simply a
sort of club, and then in 1974 we formally made it into the Intractable Pain
Society, which was, in fact, the first national pain society in the world.27 I think
we all learned a great deal from it, and, of course, not so many years later the
International Association for the Study of Pain (IASP) opened on an infinitely
bigger scale and it has proved to be enormously beneficial to all those in pain
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relief. I think the multidisciplinary idea, which John Bonica started, improved
the whole system very much and the pain clinic movement has been extremely
valuable. I am glad we are having this meeting today where we can discuss this.
Clark: Could I ask if there were connections between these two worlds of
hospice and pain?
Swerdlow: Well, certainly we were informed and perfectly well aware of both
of them and there was a lot of intercourse between people who worked in both.
Some people, of course, literally worked in both but, yes, there was an
enormous amount of throughput between the two.
Clark: Dame Cicely, would you like to add to that?
Saunders: Peter Gautier-Smith from the National Hospital for Neurology and
Neurosurgery in Queen Square, London, came and did injections for a few of
my patients at St Joseph’s [Hospice, Hackney, London]. And when we opened
St Christopher’s in 1967 Dr Robbie came from the Royal Marsden, London,
so we have always had a blocker, as it were, around. What we found was that
we used them better, but less often. 
Clark: Would Sir Michael Bond like to offer us some thoughts at this stage?
Professor Sir Michael Bond: My beginnings were different again and were
driven, strangely, by my health. I set out in life to become a general surgeon
and I was only into the training about 18 months when I developed eye
problems and had to cease. But during that 18 months at the University of
Sheffield my research project concerned the use of cancer chemotherapy agents
of various kinds, and I did my work on wards for both women and men and
noticed, in passing, the poor way in which people were treated for their pain.
It wasn’t my duty to deal with that side of things at all, I was collecting
information about the effects of the chemotherapy, but I did notice this. When
I had to leave surgery and do something in which my eyesight would not be
important, relatively speaking, I went into psychiatry. You can work in
psychiatry without actually seeing people, can look at them, but you don’t have
to see them. I didn’t reach that point thankfully, but I was very anxious to find
a bridging project between what I had been doing and the new world that I
had entered. 
It so happened that the Professor of Psychiatry in Sheffield at the time was a
man called Erwin Stengel, who was Viennese and who, in his early days of
training, had connected with Freud. So in a strange kind of way I had this
tenuous link to Freud that goes back to the late nineteenth century. Stengel
Innovation in Pain Management 
11
came to the Maudsley Hospital, London, and eventually became Professor of
Psychiatry in Sheffield.28 In the same department there were two people who
are now major figures in the world of pain seen from a psychiatric perspective,
Harold Merskey and Issy Pilowsky. When I said that I would like to study pain
in women with carcinoma, they were a great help. 
Now, I realize in retrospect that all of us were at the tail end of what you might
call the ‘psychosomatic movement’ which in itself had connections with the
Freudian psychodynamic world, because Merskey was studying hysteria,
Pilowsky was studying hypochondriasis and I wanted to study the relationship
between certain personality characteristics and pain in the women with
cancer.29 The selected vehicle was a personality construct known as the Eysenck
construct of personality, which has three dimensions. The two that were
important were neurotic–normal and extrovert–introvert. The studies on the
women showed that there were differences in the way in which they behaved
when in pain, and indeed whether they had pain or not, and the two
constructs. This prompted Merskey and Pilowsky to start thinking about pain
in relation to their own work. 
Pilowsky, who was looking at hypochondriasis, developed what was called the
Whitely Index of hypochondriasis and you can still come across that in the
literature today.30 And from that he went on to develop the Illness Behaviour
Questionnaire, linking up in due time with the work of Bill Fordyce and
others.31 We have heard about Bill Fordyce earlier. He was, I think, an
occupational psychologist who worked in Seattle [Washington] and was roped
into the pain circuit there and put forward the notion that behaviour theory
could be applied to people with chronic pain disorders. In fact, it wasn’t long
after that that it was appreciated that people are not just behaving animals,
they have thoughts as well, and of course that led on to the incorporation of
cognitive theory and so we came to cognitive behavioural therapy eventually. 
But going back to the days in Sheffield, Harold Merskey became interested in
pain and wrote his MD thesis and a book on the subject of hysteria,32 [and
later] became interested in other psychiatric abnormalities and pain. He wrote
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at some length about depression and pain and the occurrence of psychiatric
disorders in neurological clinics and in general practice, and the presence of
pain. At that time Sheffield produced three people33 who went on for the rest
of their working lives in the pain field. Pilowsky is now retired and he had
become Professor of Psychiatry in Adelaide, and now lives in Sydney. Merskey
went to Canada and became Professor of Psychiatry in London, Ontario. 
Merskey has been, I have to say, by far the most productive, because he is the
person who was responsible for leading the group within IASP that defined
pain. I am sure everybody here is familiar with the IASP definition of pain.34
He was also the driving force behind the taxonomy of pain that IASP
produced, and he has contributed significantly in a scholarly way to our
understanding of pain and the history of pain.35 Harold is a figure of great
significance. That’s where it started and I think we realized back in the 1960s,
because in general psychiatry there was an interest in behaviour therapy that
emerged at about that time, that the future of pain management by
psychological means lay in this particular methodology. It was taken up quite
rapidly and it was appreciated particularly when Bill Fordyce came along
slightly later, that the technique had promise for the management of certain
pain problems. 
I think that’s where my interest in pain started. I did eventually link up with
St Christopher’s Hospice through a chap called Ken Calman (now Sir
Kenneth, the Vice-Chancellor of Durham University and until not long ago
was a high ‘heedjun’, as they say in Scotland), in the Department of Health in
England. He was Professor of Oncology in Glasgow at one time.36 I went with
him to St Christopher’s on a number of occasions and that proved very
fruitful. I set up a clinic for the treatment of patients with chronic pain that
appeared to be driven more by psychological than physical factors, I think, in
the late 1970s–early 1980s. There may have been one other like it in
Manchester about that time or even before, but I couldn’t say for sure whether
that’s the case, but it was certainly one of the first clinics of that kind. 
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One of the students we had in the department was Professor Chris Main, who
is sitting just here in front of me. He has carried out a great deal of work on
pain and in particular with an orthopaedic surgeon, Gordon Waddell.37 I am
sure he will tell you all about it in due course. It was an unusual pairing to have
an orthopaedic surgeon and a psychologist working together, as their languages
are by and large totally different. Like speaking to an Eskimo I should think.
They had a very fruitful union over the years with respect to problems
associated with back pain.
Clark: Thank you. We have got three lovely vignettes there all in the 1950s and
1960s. I wonder if I could broaden it out and invite one or two others to
comment on that period or perhaps to ask a question. But can we just stay in
that general territory of the 1950s and 1960s and reflect a little bit more on
what was happening then. Would somebody like to say a little bit more?
Dr Leon Kaufman: I came to University College Hospital (UCH) in 1954 and
I want to endorse the comment made by Dr Swerdlow that there was really a
pain clinic in existence then, but it was a very half-hearted event. It was a block
once a month, because there was no demand for it, and patients were just sent
there as a last resort. There was an interest at that time in phantom limb pain.
We are actually talking about pain as if there’s only one kind of pain. There’s
acute pain, chronic pain, there’s reflex sympathetic dystrophy and so forth. It’s
a very wide field. But they were also looking at trying to prevent phantom limb
after amputation and the question was discussed whether in fact it was better
to do the amputation under spinal analgesia rather than general anaesthesia.
Some people felt that if you anaesthetized someone for, say, three or four hours
after the operation, the phantom limb wouldn’t appear. That was discredited
when further studies were undertaken.
At the pain clinic, we had Professor Wall who got interested, we had a
neurologist and an anaesthetist and that went very well, and now in fact it is
run by an anaesthetist, Dr Baranowski [Andrew Baranowski, Head of Non
Acute Pain Research of University College London Hospitals], between UCH
and the Middlesex. I can emphasize one thing about Peter Nathan, who was a
great man on injecting phenol. And he wrote a very interesting paper, nothing
to do with pain. It appeared in the Lancet in 1967 and was prompted by the
fact that after his mother had an operation on her hip performed by an
orthopaedic surgeon, she developed avascular necrosis. He was told it was a
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very unusual complication and he was very inquisitive and researched
information from a lot of orthopaedic surgeons and found that each often had
at least one or two cases, so it wasn’t such a rare complication. That’s why the
paper was entitled, ‘When is an anecdote?’38
Professor Duncan Vere: I think you [David Clark, Chair] asked me to
comment on concepts and management. I suppose I saw the thing particularly
from the general hospital and general practice standpoint. I will say that until
about 1965 in hospitals – general hospitals and general practice – there was
entrenched ignorance, a tremendous amount of severe pain. Patients who were
in severe pain, or dying with pain, were often given the Brompton cocktail (or
Mist. Obliterans, as it was politely known), and it was a matter of patients being
rendered so that they didn’t know what they were doing, by doctors who
certainly didn’t know what they were doing. They were using medicines with
actions that they couldn’t understand, because they had this complex mixture
of cocaine, morphine, gin, sometimes with phenothiazine added.39
Parsimony was the order of the day, which rendered control impossible. Pain
breakthrough was frequent and intermittent control of course is disastrous, if
only for the reason of the self-augmentation of pain. Hospice care had of
course begun, and all that Dame Cicely has said was known in principle, but
somehow it didn’t seem to have come across into the general medical and
surgical field in hospitals and general practice. And we wrote a paper on ‘The
hospital as a place of pain’ at that time.40 Well, the hospice concepts were
continuous effective pain control, without blotting out the patient necessarily,
and driven very much by a Christian ethical concept of care for persons
without denial of their personality. But we had the lawyers continually barking
in the wings. One particular professor from Cambridge used to preach that
you can’t control pain without killing the patient;41 and, [that is especially true]
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of course, if you use mixtures in the way that we did, it was the partial truth;
but it need not have been so. 
So – mechanisms for continuous pain control: I think there were four key
concepts. The first was the reduction of the problem to its simplest elements,
and this is where I think Robert Twycross made such a tremendous
contribution, he came as a research fellow in our department and realized that
it was impossible to control pain sensibly with mixtures. He set about asking
the simple questions: What is the relative potency of morphine and of
diamorphine? What may be done to use these drugs so that cumulation42 can
occur without intoxication?, and so on. He will no doubt say more about this. 
The second important idea was separating drug actions by accurate dosage.
Respiratory depression is not a problem if you keep the dose range within that
for pain control. 
The third important concept was how to gain cumulation of a short-acting
drug like morphine. Morphine and diamorphine were then the only effective
drugs against severe pain apart from methadone, but more of methadone in a
minute. It was important to titrate the use of the drug so that you could reach
adequate cumulation and then keep that as a threshold level.43
And the fourth important thing, as has already been pointed out, was the
recognition of the different modalities of pain and that different drugs could act
upon the different modalities in different ways. Some were effective against some
forms of pain, others against others, and the tricyclic antidepressants soon began
to be used in neuropathic pain. The other important thing, as has already been
said, is the whole question of the mind in relation to pain, the amplification of
pain by the mind, the importance of the sympathetic nervous system in the
modulation of pain and so on, all of this was being considered then. 
And lastly on the question of management. It seems to me that the important
thing was the use of clinical trials to discover efficacy, potency and the
pharmaceutics of drug therapy. St Christopher’s was very much to the fore
here, and the various research fellows were very busy with the clinical trial
work. It was quite a time before folk would feel sure about the ethics of clinical
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43 Professor Duncan Vere wrote: ‘Though the pharmacokinetics of morphine, and the half times of
effective action for the opiates were known, many doctors were using them without understanding,
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trials in this field and there was a lot of debate about that early on, but it was
realized that of course there were ways to conduct effective clinical trials as
measures in this field without breaching ethical principles. So those are really
the main points that occur to me about that period of time, 1965 to 1970,
when I think Robert came to join us.
Clark: We will give Robert Twycross the floor in a few minutes, but I would
just like to stay in that slightly earlier period if we can and invite any further
questions or comments.
Dr Colin Murray Parkes: I have been a consultant psychiatrist at St
Christopher’s since the outset in 1967 and although my primary interest has
never been pain, it was brought home to me very clearly in the early days at St
Christopher’s how important a determinant of psychological distress pain
could be, and equally how psychological distress often seemed to aggravate
pain. I directed the first evaluation of the quality of care at St Christopher’s as
seen through the eyes of surviving family members.44 We started collecting
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Figure 2: Proportions of patients with severe and mostly continuous pain.
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46 Mrs Jennifer Raiman wrote: ‘Patients liked and used the body outlines in the study easily and they
ultimately became the focus for the development of a chart to observe and assess pain control. The
body outlines were used by patients to regularly record their pain sites, together with their own
written observations and assessment ratings on the severity of pain experienced and the level of pain
relief achieved.’ Note on draft transcript, 12 December 2003.
information in 1969 to 1971 and we showed, for instance, that patients at St
Christopher’s were said by their families to have suffered severe unrelieved pain
in 8 per cent of patients, whereas at other hospitals in the area, it was closer to
20 per cent, and in those dying at home, nearly 30 per cent. When we repeated
that study, in identical form, ten years later, we found that by this time the
news had got about how to give decent pain relief in the area, partly because
of the teaching programme at St Christopher’s, and other hospitals were now
doing almost as well in administering pain relief as St Christopher’s.45
Mrs Jennifer Raiman: I would like to pick up the story, if I may. I was in
Professor Duncan Vere’s department in 1978 and undertook a descriptive
study looking at intractable pain, working with patients, staff and carers, at the
Royal London Hospital, London. The study led us to the work of Dr Colin
Murray Parkes at St Christopher’s Hospice, who also held an appointment at
the Royal London at the time. I think the key to the initiation of the study was
that the work of the hospice movement was certainly becoming appreciated in
the general areas, and its impact was beginning to be felt in the health service,
particularly in the areas of pain and symptom control. 
As anticipated from the body of work that Duncan has referred to, and the
knowledge from what was happening on the wards, it was found that the majority
of the patients referred had carcinoma, many of whom had secondary disease.
They were nearly all found to be experiencing unrelenting, unrelieved pain. 
For each patient in the study I interviewed a doctor and a nurse significant in
their care, and if possible a family member. We found that despite staff
awareness of palliative care and the success in the hospice movement, as it was
called then, pain relief was not an aim: ‘Oh, yes, they can do it, but we don’t
do it here’. It was salutary, and of great concern to find that hospital staff had
very low expectations of what could be achieved in their own area of care at that
time. It was an enormous worry and one that we tried to address with some
urgency. We used the body outlines with observation and assessment of the
patient, but it was totally patient-focused,46 so it brought both staff and patients
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Figure 3:The London Hospital Pain Observation Chart.
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3 – severe
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0 – no pain at all
S – patient sleeping
together, looking at the pain, trying to break this dreadful cycle where people
would give analgesics and go away and not go back to check that it did work. 
There was neither the knowledge nor the vigour to address the problem, and
to be frank, I became quite haunted by what I heard. And as a result of the
study we developed the London Hospital Pain Chart, which was accepted by
the hospital and the medical college, and in various ways it was adopted and
adapted in the wider health service. It may be still winging its way round
various acute wards in some form, I hope. Patients are still involved in that
way. What actually spurred us on from that was becoming linked to a cancer
charity called Macmillan Cancer Relief, who came to the London Hospital
Medical College in 1982 and asked if it was possible to set up a Macmillan
Education Unit within Duncan Vere’s department [of pharmacology 
and therapeutics].
Professor Sir Ken Calman was a founder member of this and we had meetings
with a variety of people, looking at the ways that education and training in
palliative care for professionals could be taken forward, as it was then
becoming known as a speciality.47
I was seconded to Macmillan in 1983, and later set up Macmillan’s Medical
Services Programme for the charity, which had concentrated up to that time
on the development of Macmillan Nurses. Aided by grants from Macmillan,
300 medical posts in cancer and palliative care, including training posts, have
been established since then. I am very pleased to say that there are more
training posts being developed, for specialist registrars, senior house officers.48
To link back to what Duncan was saying, in relation to the community it has
been possible for GP advisors and GP facilitators to be developed with a
particular interest in palliative care, obviously with the developments in the
whole department. The teaching of palliative care and cancer care is now on
everybody’s schedule, and the diploma in palliative medicine was established in
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Cardiff, which I think has actually linked the community, the GPs, the
community nurses, with cancer care, and we hope this will continue to develop. 
Bond: I want just to emphasize how awful it was for people in the early 1960s
and prior to that, and before the time when the work of the hospice
movement, as it was called, became generally known and accepted. Cultural
attitudes to pain were very obvious amongst the nursing staff. I was concerned
by the extent to which the patients seemed distressed by the poor control of
pain, and decided that I would conduct a small study. That would have been
about 1961 or 1962. I asked patients to estimate their pain levels, and
incidentally the analogue scale for measurement of pain first appeared in
Sheffield at about that time, and linked them to the nature of the analgesic that
was prescribed for them. I did a study on the male oncology ward and the
female oncology ward. The results were amazing, because there wasn’t any
correlation at all between the type of analgesic given and the level of pain
recorded, either before and after the analgesic had been given.49
So you could have had a bucket of analgesics in the middle of the ward and
said, ‘Take one of these. It might work’. 
The second observation was that on the ward for women all types of analgesics
were available, including narcotic analgesics, but on the men’s ward narcotics
were not available. I enquired why narcotics were not available to men and was
told that men don’t need powerful drugs like that. It is hard to believe that such
attitudes existed, but they did, and I think nowadays perhaps people forget
how much we owe to some of those in this room, to Robert [Twycross] and
Cicely [Saunders] and others, for the work they did to break down the sort of
barriers that existed, the fear that nurses had that people would become
addicted, and so forth. I think it is worth recording that life was very bad
sometimes for people with severe pain. 
Mr David Joranson: I just have a brief question for Dr Swerdlow. Recognizing
the importance of language to the understanding of history, could you tell us
a little bit more if there was a story behind the choice of the word intractable,
in naming the society the Intractable Pain Society?
Swerdlow: No, there was not.
Vere: I only wanted to add one brief comment to Sir Michael’s comments
about the prevailing atmosphere. I shall never forget going to one ward, a
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gynaecology ward, to ask whether Mrs Raiman might visit it to do some
research, and the sister on the ward said to me, ‘I want you to understand, 
Dr Vere, we do not have pain on this ward’.
Dr Alex Nicholson: I am a specialist registrar from the West Midlands.
Professor Vere mentioned that tricyclic antidepressants had started to be used
and recognized for their role in pain, and I wonder if the clinicians here, who
were active at the time when those observations were first made, could perhaps
embellish upon that recognition and let some of the younger members know
how it started.
Vere: My records seem to indicate that it was about 1977 when the
relationship between the sympathetic nervous system and pain was really
beginning to be understood with animal experiments, and tricyclic drugs were
found to be effective in that area. But there was also anecdotal evidence that in
man amitriptyline, I think it was, was effective against some forms of
neuropathic pain. I can remember being enormously impressed by the fact that
a nurse research assistant joined our department, who had had a nerve
entrapment injury some years before and had found that only amitriptyline
with nefopam relieved her pain enough to enable her to work.50 I think there
was a lot of anecdote in that area, but I don’t know more than that. 
Dr Robert Twycross: Could I come in on this particular point? I really think
it should be the persons on my left [Mark Swerdlow] and my right [Sir
Michael Bond], and I think you should insist, Mr Chairman, that they do say
something after me. But as Duncan mentioned 1977, I think it was the
professor of clinical pharmacology in Cardiff, I forget his name, who wrote a
very important paper around about then, which talked about all the ways
which tricyclics might have benefit in terms of pain control. But it was clearly
known before that, and I am sure Mark will take us back into the 1960s. But
I went to St Christopher’s as Research Fellow in Therapeutics in early 1971.
Doug Robbie, the anaesthesiologist from the Royal Marsden who dealt with
the chronic pain management, introduced me to the Intractable Pain Society,
and I started attending the society’s annual meetings.
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I think in those days I was the only non-anaesthesiologist, but the person who
I think within that small group who taught me, and I am talking about 1972,
possibly Doug Robbie himself, but Hugh Raftery in Dublin published a paper
round about then on the management of post-herpetic neuralgia using
amitriptyline and sodium valproate.51 That particular paper, which I still regard
as a landmark paper for me, changed my clinical understanding, it changed my
clinical practice, plus personal discussions at the annual meeting. That certainly
dates the use of tricyclics and antiepileptics for nerve injury pain.52 It must date
it back to the late 1960s, so with those few personal comments, I think we
should ask Mark to take it back into the 1960s.
Swerdlow: Yes, I would like to say that during the 1960s and 1970s something
new came up in so far as there was quite an expansion of knowledge and
interest in neurophysiology and neuropharmacology. We have heard a lot about
psychology and psychiatry as well. And obviously the publication of the gate
theory53 by Ronald Melzack and Patrick Wall in 1965 had a very big impact on
this and ever since.
Twycross: Can I ask whether were you using amitriptyline and an anti-
epileptic before the 1970s?
Swerdlow: Yes, and then later on of course I was using the antiepileptics in that
type of causation of pain, quite a lot actually. But obviously it’s not absolutely
infallible, unfortunately.
Twycross: Sure, but probably the early choice, the early use of those drugs
would have come about because of serendipity. It was probably serendipity and
not science originally.
Swerdlow: Yes, I think that’s a fair comment.
Meldrum: I just wanted to touch back on a couple of things that were said earlier.
We have heard a couple of comments on the resistance of staff in certain hospitals
to the use of narcotics. And I am just wondering if this was true of patients as
well, if in fact patients wind up with intractable pain problems in your experience
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and are still reluctant to take morphine or another narcotic? Or did you find that
in fact that the narcotics did not work for some types of pain problems?
Twycross: I am second generation in all this. And of course it’s the historian’s
responsibility to pigeonhole each of us in this room as to where we fit into the
total jigsaw, but I should state that in my opinion I am very definitely the
disciple of Cicely Saunders. On the pharmacological side I suppose my main
guru was Duncan Vere, so it’s great to have them both here today. But having
said that, let’s get back to the present point: the responsiveness of pain to
morphine. Like Cicely and Duncan and many others – probably all the people
involved in chronic pain management of one kind or another – we believed not
only in looking after patients, we believed in trying to disseminate knowledge
because the only way you could get good across-the-board pain control would
be to have the basic understanding and the application of those basic principles
about pain management inbred into the whole of the medical profession. 
However, I think all of us who began to seek to disseminate knowledge learned
very quickly that imparting information is not enough. The challenge was, and
still is, how to change clinical behaviour. Now for me, in the 1980s, if not
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Drug type
anticonvulsants
carbamazepine
phenytoin
psychotropics
prochlorperazine
chlorpromazine
haloperidol
hydroxyzine
diazepam
amitriptyline
corticosteroids
prednisolone
dexamethasone
analgesic
•a
•a
•
•b
•c
•c
anti-
depressant
•
•
•
anxiety
reliever
(anxiolytic)
•
•
•
•
•
•
muscle
relaxant
•
•
antiemetic
•
•
•
•
anti-
confusional
•
Table 1: Adjuvant drugs used in 1986 to treat specific types or pain or to ameliorate other
symptoms that often occur in cancer patients, which were originally developed for clinical
indications other than pain.
a shooting or stabbing pain
bsuperficial, burning pain
c nerve compression, spinal cord compression or raised intracranial pressure.
Adapted from WHO (1986),Table 6, 66.
earlier, I was having to bring in a counterbalance, in other words you had
convinced people about the use of morphine, particularly for chronic cancer
pain, you had convinced them about the regular prophylactic prescription and
the use of adjuvant medication, but then some people went overboard and it
was morphine, morphine, morphine all the way.
In my teaching, certainly by 1980, I had deliberately classified pain from a
teaching point of view into morphine or opioid responsive, morphine partially
responsive, and morphine non-responsive. And a lot of people also used the
same teaching model during the 1980s and I think it was a very interesting and
necessary counterbalance to people’s blind over-enthusiasm. And I remember
one doyen of chronic pain management and a leading light in the Intractable
Pain Society saying to me, ‘Robert, do you really believe that there are pains
which don’t respond to morphine?’ And I said, ‘Yes, I do’. Now, of course, he
knew that, but wasn’t it interesting that you can get this divorce between what
you know, if you really sit down and reflect, and what you actually do in clinic? 
I think that was a necessary period when we had to popularize, in particular,
the use of what is called by the WHO the adjuvant analgesics,54 particularly the
antidepressants and the antiepileptics for nerve-injury pain. We had to get
across this, as always, oversimplified message. And then that went too far, so in
the 1990s we had to unscramble that particular simplistic teaching model. But
practically speaking, I think we can still say that there are some pains that will
not be relieved by an opioid unless the patient is ‘drugged’ into drowsiness,
asleep. Perhaps a classic would be the pain of somatic muscle cramp. There’s
another approach to that. 
Then there are pains where you may be able to do a good job with morphine,
but only at the cost of unacceptable adverse effects in terms of drowsiness and
confusion in particular. And in those, from a practical point of view, it is best
to regard them as partially responsive and approaching them with a multidrug
approach rather than relying totally on morphine. Compared with 20 years ago,
there are probably fewer pains that I would regard as essentially totally resistant
to morphine. People might want to disagree with that, but, in practice, there are
still quite a lot of pains I would urge people to think about as clinicians as only
partially responsive and to approach in a multimodality way. 
Clark: Robert, will you hold on to the microphone, because I would like you
to take us back again if you would, because we sometimes think of you – and
Innovation in Pain Management 
25
54 WHO (1986). See Table 1 on page 24 opposite.
I think I have heard you use the phrase – as the man who destroyed the
Brompton cocktail. Can you tell us how that came about? And how you
found yourself drawn into that area of research and how you conducted
those studies?
Twycross: I am going to say something else before I answer your question. We
were combating misinformation – that was the big challenge. It wasn’t just
giving the right information, we had to undo a lot of bad learning, and a lot of
that bad learning (I think, Duncan, you may want to comment on this), came
from the basic pharmacologists in their teaching of pre-clinical medical
students and nursing students. And this of course would carry over into the
medical profession and the medical profession would repeat the same
misinformation. A lot of that misinformation came because people were
making unwarranted extrapolations from one area of research or experience
into another area of research or experience. 
I have jotted down six areas where people did not make distinctions when they
should have:
• acute vs chronic pain 
• single dose vs multiple dose
• parenteral vs oral
• addict vs the non-addict or patient world
• human vs animal
• volunteer studies vs studies on patients in pain. 
So there was this tremendous misinformation, because of confounding these
various dichotomous situations. 
So you want to move on to the Brompton cocktail? Marcia started off by
talking about various strands. Was it two strands or three strands? It should
have been three strands if you had included the hospice/palliative care strand.
But quite clearly, there are lots of strands coming through history, and I was
pleased that Mark went back to 1884. And, in the UK, whatever the majority
of people were doing in terms of non-practice or bad practice, there’s probably
been continuing good practice for hundreds of years, right from Thomas
Sydenham, who said that, 
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among the remedies which it has pleased the Almighty God to
give to man to relieve his sufferings, none is so universal and so
efficacious as opium.55
In the eighteenth century opium was often given as an alcoholic extract
called laudanum. We can assume that, after Friedrich Wilhelm Sertürner
isolated morphine from opium, we progressed to solutions of morphine.
Certainly, at the end of the nineteenth century we have two
communications in the British Medical Journal from Herbert Snow, a
surgeon at the Royal Cancer Hospital (later the Royal Marsden Hospital),
in which he wrote about morphine and cocaine solutions delaying the
progression of advanced cancer pain.56 Others were using morphine
solutions either for chronic cough and breathlessness in terminal
tuberculosis. So we have this continuing strand, the faithful few handing on
the torch from one generation to another. 
Now, it’s interesting to ask why was it not more widely disseminated? And I am
not sure that we can put the historic clock back and find that out. Anyway, I
came on the scene when I moved to St Christopher’s in March 1971 as
Research Fellow in Therapeutics. Amazingly, despite being post-MRCP
[Member of the Royal College of Physicians], five years after qualifying, I
thought that diamorphine was two molecules of morphine linked together. It
was only during my first or second week at St Christopher’s that I learnt that
it was diacetyl morphine. I have come a long way. 
What was this Brompton cocktail? Generally speaking, it was a mixture of
morphine and cocaine in honey or syrup plus alcohol. It was probably used as
a post-thoracotomy analgesic at the Brompton Chest Hospital, and as a cough
and respiratory sedative in terminal tuberculosis. So probably the Royal
Marsden and the Brompton Chest Hospitals were using the cocktail, even
though they weren’t disseminating its use. When was this formula published?
It was sometime in the 1950s in a supplement to the hospital formulary, either
at the Royal Marsden or the Brompton Chest Hospital.57 In 1958 it first
appeared in Martindale’s Extra Pharmacopoeia, and then the British National
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Formulary (BNF) and then eventually in the 1970s it was being published in
four formulations and I think again it was in the BNF.58
Going back to Duncan’s point about mixtures, he wasn’t talking about using
several drugs in a rational way, he was talking about a magic mixture. There
were four formulations side by side in the BNF, one was morphine and cocaine
plus the vehicle (including the preservative, chloroform water), and another
was diamorphine and cocaine plus the vehicle, and then there were two with
chlorpromazine added. In these latter two, there was a cerebral stimulant –
cocaine – and a cerebral sedative – chlorpromazine. One of the things I realized
early on was that for some reason people committed intellectual
pharmacological suicide when it came to treating the dying. I mean how could
people prescribe morphine or diamorphine, plus cocaine, plus a
phenathiazine? But that was how it was, and it was this particular situation that
Cicely was particularly keen to investigate. We first looked at morphine versus
diamorphine, because, on the basis of what she had been taught, Cicely had
developed the clinical impression that diamorphine had certain advantages,
but she wanted to put it to the test. And that’s what she asked me to do, and
it was a great privilege to have undertaken that particular trial, with Duncan
and with others’ help.
When the results came out in the now time-honoured four-hourly way,
individual titration to effect, there was no difference in efficacy between
diamorphine and morphine given by mouth. This of course was a tremendous
step forward, because no longer could people in other countries say, ‘Well, you
can do it because you have got diamorphine, but we’ve only got morphine’. So
that immediately made it more directly exportable, though the more
perceptive had already started exporting it, particularly Balfour Mount and
others in North America,59 having made the obvious step, ‘Well, if we haven’t
got diamorphine, we had better do our best with morphine’. 
And then we went on, while working out the results on the first trial, to look
at morphine/diamorphine, plus or minus cocaine. Balfour Mount in Montreal
investigated cocaine too. We concluded that cocaine might be of benefit for a
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few days, but there was no lasting benefit. So, if it was just relieving some of
the initial drowsiness, why complicate the issue by putting in a drug which had
potential adverse effects? Certainly people didn’t use it in the carefully
controlled way as at St Christopher’s, with a very modest dose of 10 milligrams
every four hours. In contrast, at some centres (notably in the USA) when the
dose of morphine went up, the dose of cocaine went up too, so much so that
at one hospice, they told their patients that the price of pain relief could well
be hallucinations – induced by increasing doses of cocaine. 
Anyway, there were all sorts of reasons for trying to simplify [the regimen]. We
got rid of cocaine and, perhaps once in a blue moon, a patient would be
specifically prescribed a cerebral stimulant (in those days, dexamphetamine),
but generally patients were advised to work through the initial drowsiness.
Cicely, when was the regular admixture of prochlorperazine syrup60 dropped?
We dropped it in Oxford in about 1979, when we changed to the much less
sedative, once-a-day, small dose haloperidol. We certainly simplified right
down during the 1970s. We started with what Cicely had inherited and had
used very very well. But by the end of the decade we had simplified right down
and that’s where we remain, and that’s where the WHO comes in – and the
further popularization of morphine by mouth as the standard strong opioid of
choice, particularly for chronic cancer pain.
Saunders: I can’t give the date of when we changed. I must make a short salute
to Sir George Godber, because when I was getting a clinical impression at St
Joseph’s that diamorphine was the better drug, I did realize then that you had
to test your own enthusiasms and also, as I said before, we were getting better
at everything, and it was Sir George leaning on the research department of the
DHSS that enabled a totally unknown hospice to have the money waiting to do
drug trials by the time we opened, as well, incidentally, as doing a study on what
could be done at home as a research and development project, which also
started in 1969,61 and it enabled us to show that people tend to think that a
hospice is just a building, whereas a hospice works in the community and what
has been shown is that treatment of pain in in-patients can actually be done at
home and I think that’s enormously important. As far as the introduction of
slow-action, obviously at my advanced age of 84, I haven’t been in clinical work
for some while and I couldn’t possibly give you a date. 
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Dr Peter Hunter: I would like to make an historical point about how the
innovation of cocaine as a corneal and conjunctival anaesthetic came about in
1884. Dr Carl Koller was within six months of having qualified and was
working as a trainee ophthalmologist in Vienna. One of the interesting aspects
is that Koller had understood what Freud had failed to recognize, that the single
most important action of cocaine was that it is a very powerful local anaesthetic
and the experiments that established this were completed in a single day.62
I am puzzled about serendipity and why Tegretol, an anticonvulsant, came to
be used to control the pain of trigeminal neuralgia. Tegretol was originally
synthesized in 1953,63 but it was 12 years before anybody thought of
something to do with it, which was as an anticonvulsant. How does Tegretol
affect the pathophysiology of pain?
Twycross: One very brief comment on cocaine, and then I am going to hand
the microphone to Mark [Swerdlow] to deal with Tegretol alias carbamazepine.
Just for the record, we have talked about cocaine in two different ways. Mark
and Peter Hunter have referred to it as a local anaesthetic. I was referring to it
as an orally administered drug absorbed systemically, acting as a cerebral
stimulant, and not as a local anaesthetic.
Swerdlow: Like Dr Saunders, I have been retired now for many years and not
in practical clinical practice, so although I used Tegretol many times in patients
with this particular type of pain, I never discovered just how or why it does
what it sometimes does. 
Vere: I think Tegretol, carbamazepine, came to be used because it was an
anticonvulsant, a known anticonvulsant, and tic douloureux, or trigeminal
neuralgia,64 resembled a miniature convulsion. People used it for that reason
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and then found that it was effective against a variety of neuropathic pain. I can’t
give you a date for that, but it was pretty early on in the period we have been
talking about. 
Could I just comment on one or two other dates? Amitriptyline was asked
about and, in the literature I brought with me, it looks as if Adler reviewed its
use in neuropathic pain in 1978. But there was a whole series of papers on the
mechanisms of its action and its effectiveness in human disease, going right to
1983 to Declan Walsh and other authors.65
Professor Chris Main: As a clinical psychologist, I wonder whether I could
move the discussion on to talk about non-pharmacological and non-
physiological aspects of pain. As Professor Bond said, I had the great privilege to
arrive in his department in 1976, I think, and caused him some trouble for a few
years. My interest in the field of pain was purely accidental. The first stage of my
career was extremely unfortunate – indeed many of the stages have been thus. I
did some studies on psychosomatics; I carried out a study on the outcome of
surgery for peptic ulcer the year before Zantac was introduced and the surgical
rate dropped to a tenth. So that was the end of that set of studies. I then moved
to Glasgow, but I had become interested in the relationship between people’s
perception of symptoms and what was actually happening physiologically. 
I persuaded Michael Bond against his better judgement to let me embark on a
PhD with the aid of an old 16-channel Grass polygraph which had to be hand-
scored and was maintained by an ex-naval technician who was rather too fond
of the whisky. Eventually, having gathered all sorts of information on a study
on anxiety that I was doing, the equipment failed, and so did the technician,
who was sacked one Monday morning because he still hadn’t sobered up from
the Saturday night. Coincidentally, around this time I was based in clinical
psychology just down the road from Michael Bond, and an orthopaedic
surgeon called Gordon Waddell turned up. He had been in Canada working
with the Workman’s Compensation Board there and had seen what they called
a ‘Back School’, in which four different professionals got a group of back pain
patients together to try to help them understand the nature of their problem
and perhaps do something about it. In discussion with Gordon, it seemed that
there was a clear opportunity to gather some systematic data, since he is very
careful about data, and he offered me the opportunity of an attachment to his
orthopaedic clinic. As Michael Bond has just said, I think it was probably the
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first opportunity in the UK for a psychologist and an orthopaedic surgeon to
work closely together. 
We studied a great number of patients with chronic pain of various sorts, and
many of them were surgical failures. At that time there was still a high rate of
surgery for low back pain, and we saw people who had had three, four or five
operations. It became clear that the major issue usually was not whether to
offer yet more surgery, but whether we could actually manage them a little bit
better. So we started off with a whole series of statistical studies, measuring a
wide range of variables, using all sorts of questionnaires. As you probably
know, psychologists would rather use each other’s toothbrushes than each
other’s questionnaires, and perhaps that is why there are so many
questionnaires on the market. In any event we gave a large number of
questionnaires to patients and computerized their answers. This was a painful
exercise, because in those days we had to punch cards. My entire PhD
consisted of punch cards and, on at least one occasion, I dropped the whole
damn lot. 
We carried out a series of statistical studies, tried to disentangle physical and
psychological factors, and began to construct models of pain and disability.
Our efforts were probably among the earliest attempts to quantify accurately
what people believed intuitively to be true, that is, how disabled people were
wasn’t only explained by the underlying physical factors, but by the patients’
reaction to their pain. We produced what we called the Glasgow Illness Model,
which was the basis of the biopsychosocial model of back pain disability.66 On
this occasion Michael Bond drew my attention to the fact that one of my
colleagues and myself had, in a single year, used the entire Medical School
budget for computing. 
I was then privileged to get a Winston Churchill Travelling Fellowship and this
was a landmark occasion for me. I had been encouraged to put my name
forward on the basis of the work that Gordon and I had been doing, so I filled
the form and to my astonishment was invited to Kensington Palace Gate,
where I was interviewed by a distinguished committee, chaired by Lord
Flowers, with Baroness Masham, a member of the Parliamentary Disablement
Committee, and the Queen’s surgeon and gynaecologist, Mr Pinker,67 and a
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most astonishing discussion then took place, because I knew as little about the
House of Lords as they did about the field that I was in. But they were
charming and courteous, and to my astonishment I was awarded one of these
scholarships. There were five of us from the UK, including Henry McQuay
who is not here today, who were offered the chance to go to North America in
1982 to look at new approaches to the treatment of pain.68
The important thing was that we set up a meeting on the new approaches
when we came back. We tried, as part of the mission of the Winston Churchill
Trust, to disseminate information. 
During the Fellowship I spent eight weeks sitting in pain clinics, participating
in what were called pain management programmes, which I had never heard
about. The highlight of my trip was a visit to Seattle, Washington, where I met
Bill Fordyce, a very kind man whose legacy is immense. He remains my friend
and I am one of his greatest admirers.
On my return to the UK, I was determined to set up a Pain Management
Programme, but I had a major problem. The North American clinics were set
up with between 20 and 30 members of staff, and, in 1983, you can imagine
trying to persuade the hospital administrators, as they then were, that you
needed a pain programme with this number of staff. So I decided therefore to
try to construct a honed-down version, which consisted of a physiotherapist,
one of the medical staff, and myself (as a clinical psychologist). The initial pain
management programme was for only four patients, and we were absolutely
terrified. Nonetheless we succeeded in establishing the first pain management
programme in the UK specifically for back pain in Salford.69 Unfortunately by
that time Mark Swerdlow had left the NHS, so I didn’t have the opportunity
of working with him, but I am proud to say that Salford has forged the way in
more than one era. 
Since then, the importance of learning how to live with pain and manage it has
been recognized, because we simply don’t have cures for all pain, and we can
no longer assume that for all pain there will be a pharmacological answer to
what really is part of the human condition.
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In conclusion, I would just like to consider what really has happened over the
last 40 years. The early studies by Michael Bond and colleagues did try to
disentangle psychological and physical factors, and were landmark studies, but
many of the early studies were carried out on psychiatric patients who reported
pain. We soon came to realize that general hospital patients with chronic pain
problems were different from psychiatric patients who reported pain. We
embarked on the development and validation of a whole new set of assessment
instruments to try to improve our assessment and clinical decision making.70
‘What is it that’s stopping this person from obtaining maximum function?’
Some of this can be helped by pharmacology, of course. In my view we need
to embrace much wider perspectives on pain and disability, as signposted by
the biopsychosocial model of pain and disability. 
And finally I would just like to mention that this whole area has developed from
healthcare outcomes to occupational outcomes, and the current Green Paper
which is just out at the minute on vocational rehabilitation71 is very, very much
designed from a psychosocial perspective and I think there’s some optimism that
even if we can’t cure pain perhaps we can learn to manage it better.
Dr Niki Ellis: I am a public health practitioner. Just to add that Gordon
Waddell was extremely influential with these ideas in Australia. He came to
Australia in the 1980s with the repetitive strain injury (RSI) epidemic and has
had a big impact on back pain management. 
Clark: Is there something of a divide, I sensed it in what you were saying,
between those people who deal with pain which is malignant in its underlying
causation and pain which isn’t. You are adopting this rather positive view of
what can be done about it. 
Main: I think there is an interesting interface. I have done some work in
hospices, not a lot, and I am not an expert in cancer pain, but it does seem to
me that until relatively recently, perhaps, it was assumed that adequate
pharmacological control obviated the need for a more careful look at
psychological factors. Now this is not the case in the best of hospices, but
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sometimes the whole treatment regime is so pharmacologically driven that
psychological factors perhaps have been neglected.
Kaufman: May I just make one or two points. The first recorded death from
cocaine occurred at UCH in about 1889 in a young boy who had a convulsion
accompanied by opisthotonos.72 I was concerned about the derogatory remarks
made about diamorphine, diacetyl morphine to be correct. I have been using
this intrathecally and I think the references made before have been about the
oral administration, but if you give it intrathecally, and I have been doing this
for a few patients with carcinoma, the pain is relieved immediately. Now it’s
very difficult to explain this pharmacologically, because before diacetyl
morphine (diamorphine) can act it has to be converted to morphine and
patients will get immediate pain relief if this is given intrathecally.
I have taken to anaesthetising patients, giving them diamorphine intrathecally
during the course of operations. Interesting studies measuring the endocrine
response in surgery by cortisol levels, adrenaline, and antidiuretic factors, have
shown these are all suppressed by the use of intrathecal diamorphine.73 Now
going on from that, listening to the psychological path of pain relief, one of the
research workers working on a thesis at St Mark’s Hospital (specializing in
abdominal surgery), where I was a consultant, we had three or four major
operations a day on patients with cancer. We had a psychologist come into the
theatre and watch what we were doing, and he counselled patients prior to
operations, hoping in fact that he was able to suppress the endocrine response
to surgery. To our surprise, we got the reverse. Those patients who were
counselled, who we thought would have had lower levels of adrenaline,
cortisol, and antidiuretic hormone, had high levels.74
Vere: Can I respond just very briefly to Dr Kaufman’s comments on
diamorphine, diacetyl morphine. The point is that diacetyl morphine is much
more liposoluble and able to cross the blood brain barrier and if it is de-
acetylated it does so in two stages: first to 6-monoacetyl morphine, which
enters the brain very readily, and so of course it works quickly. Every addict
knows this, this is why they prefer it strongly to morphine, because they get a
rapid ‘buzz’ as they call it when they inject intravenously. 
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Kaufman: Point taken, but that conversion takes place in the liver and that
takes time. This is an immediate response.
Vere: No. Diamorphine is already diacetyl morphine and so it crosses the
barrier. It is very soluble.
Kaufman: I agree, but the fact is that the conversion to morphine doesn’t take
place at the spinal cord level.
Vere: No, agreed.
Kaufman: But this comes on immediately. The patients are unaware when an
injection is being given and they say, ‘Doctor, my pain has gone’. 
Vere: You inject diamorphine dissolved in saline; this is changed very quickly
in solution to 6-monoacetyl morphine which enters the nervous system very
rapidly. Then it is rapidly broken further to morphine, though no one knows
where. But the result is an extremely rapid analgesia. 
Kaufman: That’s correct.75
Clark: We have been concentrating very much on the clinic and on the laboratory
and after tea we are going to widen out and look much more at pain in a public
health context, but with just a few minutes left, I am anxious to give anyone who
has not yet spoken an opportunity to speak, or indeed anyone who has a question
to put to our distinguished audience today to take that opportunity. First of all,
of those who have not yet spoken, would anybody like to speak or ask a question?
Hunter: I come under the question category. I would like to ask two brief
questions. First, could Jennifer Raiman tell us a little bit more about the
London Hospital pain chart, how it’s used, and who uses it? And second I
would like to ask any pharmacologist in the audience if there are any drugs that
are active on the spinal wind-up mechanisms of pain?
Raiman: The chart was developed for use by patients and staff working
together. Patients draw their pain, noting the level of severity on the body
outlines. It comes as a great surprise to many people that there is more than
one pain. The intention was that it was patient-focused, and the chart permits
the patient to open out so that they could have a better idea of where their pain
was. Both medical and nursing staffs use it when talking to the patient about
their pain, when administering analgesics, and record the analgesics given on
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the chart, along with the level of pain present. If the analgestics work, patients
receive them four-hourly. The nurses would return between the doses to note
and treat unresolved or breakthrough pain. There was room on the chart to
record what was affecting the pain, and indeed what was not affecting it, and
patients were also asked about other things that relieved their pain. The chart
was to be as broad-based as we could get on a manageable piece of paper.76
Vere: Could I just comment before answering Dr Hunter’s question? One of the
first patients who responded using the pain chart, with the body outline, was a
patient of mine with carcinoma of the bronchus with secondaries in the cervical
spinal and he was a well-known artist; he drew his ‘pain’ and it extended out
beyond his body figure. He drew it very beautifully, and I remember asking him
why had he gone outside the outline and he said, ‘Well, that’s where my pain is,
that’s where I feel it, that’s what it’s like’. And this of course was similar to stump
neuroma pain that extends beyond the actual physical anatomy of the body, but
it’s how it is perceived, and that leads directly into Dr Hunter’s question.77
I think the key paper is by Marshall Devor in 1984, a paper to the Wenner-
Gren Symposium78 where he talks about some delightfully executed
experiments, where lesioned paws in animals became imprinted in the spinal
cord with the map of the pain-responsive neurons, and echoing circuits set up
with transition ultimately up to the thalamus, and this can be blocked early on
in the first 24 hours by vincristine/vinblastine-type drugs, the vinca alkaloids
derived from the Madagascar periwinkle, which block the physical transmission
of the carriers of information from peripheral receptors to the dorsal root entry
zone in the spinal cord. But then later you can’t block it in that way. You can,
of course, gate it also by pain, which was Melzack and Wall’s great discovery.79
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Clark: I would just like to ask Dame Cicely, if I may, one question in
conclusion. Harold Stewart’s name was mentioned very, very briefly. Could
you tell us a little bit about Harold Stewart80 and how he drew you into his area
of work?
Saunders: I knew him because he used to play tennis with my father. My
father happened to meet him at Wimbledon and said that I was coming to the
end of my time at medical school and house jobs and wanted to work on pain,
and he was at that time, before he had become professor, head of the
department of pharmacology at St Mary’s, and he was working with animal
pain and wanting very much to get access to patients and finding it quite
impossible to do that in the hospital. And so he said that there was a family
trust that could produce some money and so that’s how we got together. And
he went on and supported me, because he expected me to do a respectable trial,
and after I took him round St Joseph’s Hospice, Hackney, London, when I had
been there about three months, he said, ‘Well, I can see what’s happening, do
a descriptive study, keep your records,’ and with the idea of doing a double-
blind which we had looked at, really fell into abeyance. He has only very
recently died himself,81 I think the thing about him was that he was prepared
to pick out something that was outside his ordinary experience and let me run
with it, and I am terribly grateful to him, because it wouldn’t have happened
without him.
Clark: We are now going to widen the focus from where we have been, both
conceptually and geographically, and turn our attention to the question of
pain, not so much seen as a problem in the clinic or in the laboratory, but as
a wider problem within society and perhaps particularly within the public
health systems of different societies and different countries. I would like to
begin by asking Dr Mark Swerdlow to introduce this topic to us, and to speak
about his early links with Jan Stjernswärd, who will then talk for five or ten
minutes about his work at WHO. 
We will move on to David Joranson from Wisconsin to talk about the work
that he’s doing on the development of pain relieving programmes in the poorer
regions of the world. So that’s our broad agenda. Others please contribute as
we go along, and then about ten minutes from the end, I am going to offer an
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opportunity for a kind of mop-up session to pick up on any comments of any
kind that people may wish to make and which we have not heard yet. 
Swerdlow: I would like to go back to something like 1980. At that time the
treatment of patients with cancer pain, which obviously was a kind of pain
which urgently needed relief, was by no means satisfactory, and it was very
fortunate indeed that Dr Jan Stjernswärd was appointed head of the cancer
unit at the WHO. After his appointment he started a programme, one element
of which was relief of cancer pain and I was asked to join his department to try
to help. We both felt that if patients in the poorer parts of the world, and even
in the richer parts of the world, couldn’t actually get their cancer cured,
relieved and treated, then at least we ought to try to relieve their pain. 
We set up a study in three developed countries and three underdeveloped
countries to see what the situation was at that time, what sort of treatment
patients were receiving and what sort of relief, if any, they received. At that time
Jan sent me to two or three very poor countries, to see actual cancer patients in
hospital, and it was pathetic to see the worse-than-basic conditions within the
hospitals. I remember the women’s ward in one hospital in Sri Lanka in
particular – there must have been 12 or 14 women there with really advanced
cancer – and as I walked round the ward, none of them seemed to be in great
pain. I asked the young doctor who was in charge of this ward what treatment
they were receiving. He said, ‘They get two tablets of aspirin a day’, (I think it
was) and I just couldn’t believe it. I asked, ‘Do they not receive anything except
two aspirin tablets a day? Don’t they get any sort of native herb treatment of any
kind?’ He said, ‘Well, yes, they do get a native medication,’ and when I asked,
‘What’s in the native medication?’, he said, ‘Oh, I don’t know that’. (I have
often wondered since then why somebody hasn’t gone out there to study those
herbs and what’s in them, because they looked to be pretty effective.) 
Jan and I decided that we should try to get WHO to study the problem of
relieving cancer pain, and we enrolled some of the leading clinicians in the
cancer pain world – quite a few of whom are here today. We then set up two
major meetings at which the problem was studied and where the cancer pain
ladder principle was gradually worked out.82 Several years later this was
broadcast by WHO to the medical services in every country in the world. It
was of great benefit to cancer sufferers, and WHO did a wonderful thing, and
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are still doing so. Now I would like Professor Jan Stjernswärd to talk about this,
as it was very much his project. 
Professor Jan Stjernswärd: What motivated me to make pain and palliative
care a priority in the WHO Cancer Programme, when reorienting it as newly
appointed Chief of Cancer in 1980, was the suffering I saw in my African
patients at the the Kenyatta National Hospital, Nairobi, Kenya, when doing
clinical research there in the mid-1960s. Over 50 per cent of the children with
Burkitt’s lymphoma were cured by mono-chemotherapy. The great majority of
the patients, however, were late-stage incurable solid tumours, to whom
offering therapies was like peeing in the desert, you go five metres and on
looking back you see no trace, no effect. I realized that the most relevant
human and pragmatic thing to do would be to offer pain relief as an integrated
part of any comprehensive cancer control effort.
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Figure 4: Some of the 1982 WHO group at the Villa D’ Este on Lake Como, Italy.
L to R: John Bonica, Mark Swerdlow, Robert Twycross, Kathleen Foley, Vittorio Ventafridda,
and Jan Stjernswärd.
Between 1980 and 1996 I formulated an action programme implementing the
already accumulated knowledge in cancer control in a pragmatic rational
public health way, putting science into practice, especially in developing
countries. Together with epidemiological colleagues, we established data
showing that two-thirds of cancer patients were in the developing countries
and most were incurable due to late diagnosis. Numerous technical manuals
including those for cancer pain relief, policy guidelines for implementing the
technical methods in a public health way, e.g. for pain relief and palliative care
and for the National Cancer Control Programme were done.83 I established
and advocated concepts such as ‘one-third preventable, one-third curable,
palliative care to two-thirds’; ‘cancer is a Third World problem too’; ‘freedom
from cancer pain’; ‘down staging’; and ‘National Cancer Control Programme’
and ‘WHO three-step pain ladder’. Several demonstration projects,
collaborating centres and numerous National Pain Relief and Palliative Care
Programme/Initiatives around the world were supported by WHO and a
worldwide network of achievers in pain relief and palliative care were identified
and built up.
Pain as one of the most common symptoms was selected as the symptom to
address.84 For palliative care the philosophy and ethics were simply that the
same attention and care given to those entering life, the newborn, should be
given to those leaving life, the elderly and chronically ill. The pain relief and
care I had seen in hospices only reached a few, often 200–300 patients a year,
while many more were in need, perhaps 200 000 getting nothing. However,
the hospices served as lighthouses showing the way in an ocean of suffering. As
a specialist in radiotherapy/oncology I had not received a single hour of
education in pain relief. I therefore decided to contract a pain specialist as
temporary adviser to the programme. I found that Mark Swerdlow was
available, then 62 years old. He had read an article in the Lancet arguing that
if you retire when you are 62, you would live longer, especially if you walked
rapidly for an hour every day. In his case he also played the violin regularly. You
can see that he looks happy and healthy still today.
Mark advised me ‘who was who’ in the pain-zoo and stressed that ‘you must
see Vittorio Ventafridda’, who also happened to be around the corner in Milan.
In the cafeteria in WHO Geneva, Vittorio drew, on a paper serviette, the
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principles for what would later become the ‘WHO three-step pain ladder’.85
The paper serviette is somewhere in one of 46 unpacked boxes in my attic at
home. Jointly with the Floriani Foundation, Milan,86 WHO held an informal
meeting87outside Milan in an old medieval castle where we locked up some of
the feudal lords in pain control. My charges to them were, ‘I want a simple,
effective, scientifically valid method for pain control, applicable, affordable and
maintainable at community level’. That is, the public health approach together
with policies and strategies for its implementation, so it could reach everybody
in every country, and also in the developing countries were the need is greatest. 
In spite of the fact that Cicely just called Mark ‘a blocker’ he was not blocked
totally in his attitudes, for as chairman at the meeting he could accept this
simple approach. However he was, and I am afraid still is, very much in favour
of the needle and nerve blocks. 
A draft guideline for cancer pain relief was produced in 1984.88 On return to
Japan, Dr Takeda immediately tested the method in 154 patients.89 It was
controlling pain in most of the patients. Several other tests, in over 3000
patients,90 showed the validity of the WHO three-step ladder [see Figure 5].91
I myself was convinced testing it in Geneva with Henri Rapin, at Centre Soins
Continue.92 I saw a woman, grandmother, full of breast cancer metastases,
lying facing the wall in agony, sweating, moaning as the doctor passed the
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room – as did the physiotherapist and the family – with the nurse being the
only regular visitor. We put her on the ‘three-step pain ladder’ and after a week
she was at home, pain-free, taking care of herself, coming back only two days
before dying in hospital three months later. We treated 124 patients and I was
convinced that the method worked. 
I now needed to have the ‘WHO three-step pain ladder’ made official. I
succeeded in getting extra financial support from the German Ministry of
Health, courtesy of Dr Helmet Voigtländer, to hold a WHO meeting to
finalize the draft guidelines in December 1984 with experts in cancer pain
management, in national and international legislation concerning the
regulation of opioid drugs, in healthcare delivery, education, pharmaceutical
research and manufacturing as well as representatives of several international
non-governmental organizations, altogether 36 persons, geographically
balanced. The ‘WHO three-step pain ladder’ was officially born.93
The extent of the problem – reasons for inadequate control of pain and
barriers – was addressed and comprehensive cancer pain management outlined
in detail. Education and training, legislative factors and substance abuse and
organizational aspects were also covered. Robert Twycross was the rapporteur
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Figure 5:The World Health Organization’s three-step pain ladder, which recommends medicines
of increasing strength if pain worsens. WHO (1986), see note 91. See also Table 1, page 24.
STRONG OPIOID +– NON-OPIOID
+– ADJUVANTS
if pain persists or increases
WEAK OPIOID +– NON-OPIOID
+– ADJUVANTS
if pain persists or increases
NON-OPIOID
+– ADJUVANTS
1
2
3
of the meeting. We locked ourselves up for two weeks in WHO and Robert
sharpened 100 pencils and we met every day with the mantra of ‘simplify,
simplify, simplify’. Robert was so successful that a simple guy like me could
understand it. I imagined being back in Kenya, having to use the book at
Narok District Hospital in Masaai land as the only source for practising pain
control. The book became the second WHO bestseller, started to appear in
English, French, Spanish, German, Italian, Japanese, Russian, Portuguese,
Turkish and Arabic and is now translated into over 20 languages. The method
is now the standard in most countries. Its rapid acceptance is largely because
all the participants took ownership of the book and method. You always know
who the mother is, but not always the father. The method was published in the
name of WHO, no one author or editor was singled out, so everyone present
could claim parenthood to the method. Although I often have been introduced
as the father of the ‘WHO three-step pain ladder’, it is Vittorio Ventafridda
who is the real father.
For optimal effect and its implementation as a technique/method I felt it
important that priority-setting policies, strategies and managerial needs be
addressed as well as proper advocacy. A WHO Expert meeting on Pain Relief
and Palliative Care met in July 1989,94 and the concept of a national cancer
control programme where palliative care is incorporated as one of the major
building blocks, together with primary prevention, was launched, along with
therapy linked to early diagnosis for increased efficiency.95 Strategies for
incorporating pain relief and palliative care into the clinics were outlined, and
foundation measures for an effective national programme were outlined. These
measures cost little, but will have a big effect. This includes the triangle of
education, drug availability and policies. It is important that these activities be
coordinated, done simultaneously for effect. Thus, education without the
drugs being available and the inability to practise is not very effective and vice
versa, drug availability without education guaranteeing confidence in the use
of morphines is not very effective. Recommendations to governments on how
to establish a national programme were given. 
I wanted a guide for outsiders of all unknown steps needed for making opioids
available. A grant from the Drug Directorate of the Canadian Department of
Health and Welfare permitted a young, brilliant senior consultant and
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pharmacist, N R Donaldson, to be seconded from the Drug Directorate to the
Cancer Unit at WHO. Donaldson produced excellent, clear stepwise guidelines
that were to be included in the second edition of Cancer Pain Relief. 96
Unfortunately he never saw his product published as he died prematurely.
I addressed many international and national meetings around the world while
WHO Chief of Cancer, and these offered a good opportunity for advocacy.97
It was estimated that 24 million people would have read these articles. An
indirect indicator of possible impact could be the increase in morphine
consumption, as documented by the International Narcotics Control Board
(INCB), a UN organization in Vienna.98 Morphine consumption between
1972 to 1984 was under two tons a year, and since 1984 has it steadily
increased and is now up to 25 tons annually. Earlier it was around 1mg per
capita, now up to a global mean of 6mg, and in the UK it has reached over
15mg per capita. 
WHO launched its programme in 1984. We have, however, failed in India, the
greatest producer of opium. In spite of early efforts to make affordable
morphine easily available,99 consumption has gone down recently, approaching
zero. We estimate that less than 3 per cent of India’s one million cancer patients
get adequate pain relief today.
Noreen Theo, a Chinese/Burmese pharmacist in the US, joined the Cancer
Unit at WHO. She knocked at my door and said ‘I offer my services, I like
what I see’ and she was the one that made official contact with the INCB, who
mainly addressed the regulatory polices for the restrictions of use of opioids,
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but added a policy to support a more liberal use of morphine in patients with
severe pain, as it should be their right to have freedom from pain.100
Several WHO collaborating centres covering pain relief and palliative care
were established. Three of the most active were in Wisconsin, Oxford and
Saitama, Japan. The Wisconsin Centre produced the journal, Cancer Pain
Relief, with Sophie Colleau as active editor. David Joranson was later
appointed as Director and has never disappointed. He speaks the language of
the regulators. I also asked him and Robert Twycross, as Director of the
WHO collaborating centre in Oxford, to help with morphine availability in
India. An outstanding educator, Twycross was asked to address education in
India, and since then Robert has given at least two to three weeks twice a
year for education on palliative care in India concentrating on supporting
the Calicut WHO Demonstration Project, which by now is running itself
admirably and conducting the first regular Indian palliative care courses and
diplomas. Gilly Burn was the first to respond to my challenges and has been
an outstanding advocate for pain relief and palliative care in India over 
the years.101
Eduardo Bruera brilliantly lead and coordinated the introduction of the WHO
public health approach for pain relief in Latin America, addressing the need
for drug availability, education and policies in coordinated efforts. One
outcome was the Florinapolis Declaration.102 In eastern Europe Jazek Lucak
lead the development from Poland reflected in the Poznan Declaration.103
Several successful WHO demonstration projects were supported, such as the
Wisconsin Cancer Pain Initiative in the early 1980s, started by June Dahl104
and later spread like wildfire to most of the other states in the USA.
The demonstration project in Catalonia, Spain, has successfully shown the
importance of a joint governmental and non-governmental approach and the
possibility of achieving effective coverage within a ten-year period for the
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majority of the terminally-ill geriatric, cancer and AIDS patients, including
effective home care through a rational, integrated approach.105
The Calicut Demonstration Project in the state of Kerala, India is an
important model for the world, showing what can be done at community level
for the people, with the people and by the people. Suresh Kumar is here today
and can give further details. India is made up of over 500 districts, with between
2 to 5 million people in a district and that is where the patients should have
their pain relief and palliative care. Calicut district has 4.5 million people and
already most of the terminally ill are getting palliative care. The safe handling of
opioids at community level has also been demonstrated.106 Kerala, with 38
million people, was the first state in India to introduce a ten-year state cancer
control action plan and it included pain relief.107 Kerala now produces its own
immediate-release morphine (IRM) costing around US$0.01 for 10mg.
Uganda is another success story as a model for Africa and, like Catalonia,
shows the importance of an integrated governmental and non-governmental
hospice approach using WHO foundation measures.108 They have introduced
IRM solutions manufactured in the country costing less than the price of a loaf
of bread for a three-week supply, and have made pain relief and palliative care
for the terminally ill a priority in their national health plan.109 When selecting
opioids for a national initiative it is critically important first to establish clear
policies, as several initiatives have failed due to a lack of clear targets. Thus,
when the country tenders for IRM none of the large international
pharmaceutical companies answers. Instead, the companies’ aggressive
marketing, directed towards doctors, that promotes the use of expensive drugs
for routine control of pain makes the programmes non-sustainable.110 A
monthly dose costs up to two-thirds of a nurse’s salary or more in many
countries instead of the few dollars that IRM should cost for a month’s supply.
Nor are these drugs better than IRM. The risk of misuse is, on the other hand,
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much greater. Having worked hard on establishing policies for availability of
affordable morphine, it is destructive to see how the pharmaceutical companies
march in and outsmart us by aggressive, unethical marketing of unaffordable,
but not better, drugs. Fentanyl patches in hot countries on hairy people is not
recommended and may cost up to two-thirds of a nurse’s salary for one
month’s supply. I just came back from Mongolia a week ago and only MST
was available for a selected few, costing US$120 for a week’s freedom from
pain. This is many times more than the monthly salary for a great part of the
population. However, seeing the price of IRM in Kerala and Uganda gives
hope that freedom from pain may become a reality also for the great majority
of sufferers, who live in developing countries.
When choosing opioids for a national public health policy in which the
government will provide affordable or free medications, the criteria outlined in
Appendix 2 should be followed.111
Clark: I will ask David Joranson to continue in that line. 
Joranson: Well, it’s really a pleasure to be in the same room with you. I see
myself as a student of history, so having a chance to contribute something to
this process is really a thrill. I thought I would reflect on how the Cancer Pain
Initiative began in Wisconsin at the time that Jan was talking about, which was
when the WHO Programme was taking shape for the rest of the world,112 and
how we connected with WHO. I will provide you with some data about what
has changed and what hasn’t changed since 1980 and I would like to make a
few comments about what has happened in India, because I know you are very
interested in that, especially since we have Dr Suresh here. 
I have to admit that I am a former drug regulator, some people regard me as a
‘recovering’ regulator. I got my start as the administrator of the state
Controlled Substances Board in Wisconsin in the mid-1970s, and later in the
1970s my colleague Dr June Dahl joined the Board. She was and is Professor
of Pharmacology and teaches medical students about drugs and pain. In 1984,
our enlightened US Congress proposed legislation to make heroin available for
the relief of cancer pain in the US. We carefully considered this legislation
because the cancer pain problem was serious in the US and in Wisconsin, but
we could not understand why physicians in the US who were already afraid to
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prescribe morphine would suddenly embrace heroin. We did not want to do
anything that would hold out false hope for cancer patients and their families. 
We took the opportunity to meet Dr Robert Twycross at a conference in Rye,
New York. As I recall, he announced when he took the chair that when he had
left the plane at Kennedy International Airport, ‘I could smell the fear of
addiction in America’. He reiterated this several times, that if you have
morphine, you don’t need heroin. So it was on the strength of that kind of
thinking that the Controlled Substances Board opposed the heroin legislation,
but went to work to develop a positive programme more directly aimed at the
problem of cancer pain, the Wisconsin Cancer Pain Initiative (WCPI).113 This
effort involved an interdisciplinary group and a lot of education as well as
evaluation of the barriers. As Jan mentioned, he was with us in December
1986, to inaugurate the initiative, and he made the WCPI a demonstration
project for WHO. It was a very important moment in our development, as you
might imagine, to have the support of someone like Jan as well as people like
Dr Twycross and Dr Kathleen Foley.
The WCPI specialized in education aimed at practice change. Dr David
Weissman, at the Medical College of Wisconsin, and Dr June Dahl put together
an educational programme called the ‘role model programme’, which was
funded by the US National Cancer Institute.114 It was evaluated and it proved
to be an effective way of using a short amount of time and a minimum amount
of educational resources to actually make changes in physician practices with
respect to pain relief. We studied the barriers to cancer pain relief in Wisconsin
and in the US; our first job was to conduct a review of the literature that was
available about barriers to cancer pain relief. After reviewing our early articles, I
find that the barriers then appear to be the same as they are now. We know some
more about them now, and we probably classify them similarly: those that relate
to the patients themselves and the family members, to the healthcare providers,
the healthcare system, and to regulatory issues. 
In the US we found there was great variation in opioid policy among the
different states.115 In the state of Washington, which has been mentioned
several times today, we found that the State Medical Board actually
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discouraged the use of narcotic drugs in the treatment of chronic pain. That
policy persisted for quite a few years and was finally reversed.116 Opioids are
now seen as part of the medical treatment of pain in the state of Washington.
I think that the earlier policy probably expressed the view of the
interdisciplinary pain clinic movement, which essentially excluded the use of
opioids in the treatment of chronic pain. But now that view has been modified
to a large extent. 
The state cancer pain initiatives have grown to where there are initiatives in
almost every state, managed by the American Alliance of Cancer Pain Initiatives.
The Alliance has a website where you can search for cancer pain initiatives.117
My next point is the relationship between the international narcotics
regulatory system and the decision of WHO to put morphine on the third step
and call it an ‘essential drug in the relief of cancer pain’, which was entirely
correct. But this decision also necessitated developing relationships with
narcotics authorities at the international and national level, in order to
ensure that these drugs are made available, because they are so tightly
restricted, in some cases almost like nuclear material. Jan has described to
you how WHO made this initial link to the INCB in Vienna. I was at the
INCB in Vienna last week and they still remember Jan, and they still
advocate the appropriate medical use of opioids. Throughout the world they
are even called ‘opioids’ now, instead of ‘narcotics’. But in many countries,
the use of narcotic drugs is still a fearsome thing, and they are extremely
tightly regulated. For example, Peru recently changed its national law to
increase the amount of morphine allowed for an outpatient from a 24-hour
supply to a 15-day supply. Opioid prescribing policy has been very strict in
Italy and that too has changed recently. 118
There are a number of other examples. I will use morphine as short-hand for
the other appropriate opioids as well, all the full agonists. Their consumption
for medical purposes has changed a great deal since the benchmark of 1980. I
would like to refer to the two graphs (page 51), which show morphine
consumption in milligrams per capita from 1964 through 2000. As Jan
mentioned, the consumption of morphine for medical purposes throughout
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Figure 6: UK and US: Consumption of morphine, 1964–2000.
Figure 7: India: Consumption of morphine, 1964–2000
Sources: International Narcotics Control Board; United Nations Demographic Yearbook 1999.
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the world stayed relatively low and stable until the time that WHO released its
guidelines in the mid-1980s and then began to increase, at least in some
countries. The dotted line represents the global mean. The global mean in
1980 was 0.7mg per capita throughout the world, and there were no countries
that consumed more than 10mg per capita. By the year 2000 the global mean
had jumped to 51/2mg per capita and there were more than 14 per cent of the
135 recording countries that were consuming more than 10mg per capita. You
can guess which they are: countries in western Europe, North America,
Australia, and so forth. 
I have to emphasize that even in 2000, 61 per cent of the 139 countries that
reported statistics to the INCB still consumed less than 1mg per capita, and it
is these countries that represent the vast majority of the world’s population.
Africa, India, China, and most countries in Latin America, consume still less
than 1mg per capita. I am led to conclude, after discussions with Jan and many
others around the world, that the progress that has been made to improve the
availability of morphine has occurred in the easiest places in the world, that is
to say, mainly in industrialized countries that have functioning healthcare
systems.119 Most of the world’s population still lacks ready access to opioid
analgesics such as morphine. 
A few comments about India, then I will subside and turn it back to our
Chairman. Many of you are familiar with the pioneers who worked in India
and who have visited there frequently.120 Jan has mentioned their names. My
first visit was in 1990. Jan asked me to help set up a project there. It was a
dismal failure. For reasons that we both now understand, you can’t put
morphine in a hospital where there isn’t a clear understanding of its value and
confidence in its use. So we went back to the drawing board and began to meet
the people in India who were making a difference in palliative care, especially
those in Kerala, like Dr Rajagopal and Dr Suresh Kumar from Calicut. Later
we realized that throughout the 1980s, the same period that WHO was
making its big palliative care push in India, the consumption of morphine was
decreasing every year. The harder we worked to improve palliative care, the less
morphine there was in the country. That is chronicled in Figure 7. You can see
that while there had been morphine consumption in India, although well
below the global mean, India nevertheless had consumed some morphine prior
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to 1986. Jan, I think that was injectible, parenteral morphine in ampoules, and
I think you are correct that it was not tablets, because tablets were not yet
permitted by the Government of India. 
No sooner had the tablets become available, than the Indian Government
passed a law that imposed extremely tough new regulations and penalties.
Historically, the British Government of India had relied on taxation on the
cultivation and sale of opium for revenue to purchase tea and silk and other
things from the East. The revenue bureaucracy that was established in India
under the British Raj collected excise taxes that helped the finances of
government in a big way. It was this opium taxation bureaucracy that
eventually assumed responsibility for the licensing of medical morphine in
India. Under this bureaucracy it was almost impossible for a hospital to obtain
all the necessary licences to be able to obtain a shipment of morphine. And
then in 1985 the Indian Government became even tougher on narcotics, so
tough that several generations of physicians and pharmacists backed away from
using the drug any more. That was the reason why morphine consumption
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Figure 8:Workshop held in New Delhi.
declined through the late 1990s. But as a result of our group’s projects with
Indian colleagues and with which Jan is familiar, and Dr Suresh as well, a
number of workshops were held and changes were made in India’s national
narcotics policy as well as those in the individual Indian States. The
consumption of morphine in India has begun to rise again in direct relationship
to its use for palliative care, especially in Kerala, but not only there.121
I could conclude with one additional point. For those of you who are interested
in a global view about the nature and extent of barriers to the availability of
opioids, I would refer you to the report of the INCB for 1995.122 The report
contains the results of a survey of all governments in the world, about what they
thought were the impediments to making morphine available for the relief of
pain. The highest ranked barrier was fear of addiction. The second was excessive
regulatory restriction of narcotic drugs, and that was ranked equal with
inadequate education of health professionals. I think this brings us right around
to where we are today. 
I will just close on a story, one that I remember very fondly. It involves Dame
Cicely, whom I met for the first time in Singapore, in the mid-1990s at the
Hospice in Asia Conference. I was eager to ask you a question. I wanted to
know if you thought that health professionals and patients in the UK were as
afraid of addiction when morphine is used for pain as they are in the US. I
then got your permission to crawl into the back of this little, tiny car you took
on a hospice tour.
You said that in the past doctors and cancer patients hadn’t been very
concerned about addiction, but recently you had sensed that some of the
doctors were getting more concerned because of what they had read in the
media about narcotics abuse. I don’t know if that still stands at this point or
not, but I think that the fear of addiction, and what we have taught people
erroneously about addiction and opioids, is the top barrier to making opioids
more available for the relief of cancer pain in just about any part of the world,
especially developing countries. 
Clark: Well, thank you very much indeed to all three of the speakers who have
introduced this topic. I am going to throw it open now to the rest of the floor
and begin with Dr Suresh Kumar from Kerala in India.
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Dr Suresh Kumar: I come from a very different part of the world than most
of you. Our situation is quite different from the West, so the major challenge
for most of us working on the other side of the world is to evolve a model
appropriate to the social ecology. A small group of doctors and social workers
in Kerala, the southern state of India, have been experimenting with models of
palliative care over the last decade. We started in 1993 with a small outpatient
clinic in a teaching hospital in Kerala. Over the last nine years it has expanded
to more than 30 clinics spread all over the place, with associated home care
programmes. But the problem with this model is that there is no continuity of
care. The patient attends the outpatient clinic, or the home care team see the
patient at home, but since the patient is at home in the community there’s no
continuous real access to the clinic and also the coverage is patchy. 
We have been trying to work on this and after a lot of deliberations, last year,
in August 2001, we started a new programme. It’s on a trial run in a small
district, one of the poorest districts in Kerala, Malappuram, a district with a
population of 4 million. It’s called Neighbourhood Network in Palliative Care
(NNPC), aimed at training helpers and volunteers in the community and
supporting them with trained professionals and with the local palliative care
units acting as nodal centres for the activity. It has run for a year now of a three-
year project, a very ambitious one, aiming to achieve a coverage of 60 per cent
of all the patients in need of palliative care, and not just cancer. We have made
some preliminary assessments in this first year. The area now has something
like 30 per cent coverage. I am talking about a place where the daily per capita
income is something less than 50 pence and all the running expenses for the
project are raised locally. The money for training is initially through funding
from abroad or another part of India, but it’s a sustainable project. We aim to
achieve something like 60 per cent coverage in three years. Malappuram is a
small district and India has something like 530 districts. It’s a small beginning.
For the first time in a decade I am feeling that we are on the right track.
Clark: Are there other people in the room who have had experience of cancer
pain problems in this global international context and would like to comment
on it?
Bond: May I ask a question of the previous speaker? To what extent are local
government agencies backing your project and do they put any resources into
it? And if so, what do they put into it? Do they give you sufficient, 50 per cent?
Just a little, are they interested?
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Kumar: The state of Kerala has been supporting us. When you take the state of
Kerala as a whole, the Government is not yet involved much financially. But
when it comes to the new experiment that I mentioned in Malappuram, the
local people themselves raise the money. They are the main supporters
financially and also morally. Again, it’s true that once the community gets
involved it is difficult for the local politicians not to take notice. So the people
in Malappuram are getting very active support and part of their funding from
the local government.123
Twycross: I have enjoyed the comments by Suresh and David [Joranson], and
of course Jan before that, but David has underplayed the horrendous task it
has been to move things forward in India. David’s been a wonderful advocate,
badgering away at the Indian Government and badgering away in various
states, and just keeping it up has been a tremendous task. India will owe a lot
to David when the story is fully told. 
I would like to emphasize that it is the united States of India. There are some
30 states, and morphine is produced in tablet form in only four or five of
those states. The regulations meant that you not only had to have a licence to
hold morphine in your institution, you had to have a licence to transport it
from one state to another, because you were crossing a state boundary. If you
moved it from Tamil Nadu to Kerala, you needed an export/import licence,
and, of course, the bureaucracy (which I am told was bequeathed to India by
the British Raj) was so efficient that it made this either impossible or nearly
totally impossible. 
In the early days, palliative care clinics would perhaps have 100–200 patients
receiving morphine and, because of all the red tape, the morphine would run
out. What do you do with 200 patients who need morphine, and there is
none? That’s the sort of problem that Suresh and his colleagues had to cope
with. There’s a saying that what Kerala does today the rest of India will be
doing in 50 years time. So far, only about 3 per cent of the people in India who
need good palliative care receive it; there’s still 97 per cent to go.
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Kumar: Thanks to David’s efforts, the Government of India sent out a circular
to all the states,124 suggesting that they modify their narcotics regulations to
enable the medical use of morphine. Eight states have since modified their
rules. My point is that even after these eight states have changed their
regulations, morphine is freely available for medical use only in Kerala.
Basically, it is one thing to amend the rules, and it is another to create a
demand. Even if you have amended the rules, if you don’t have the machinery
to implement the change, the new rules may not serve much purpose. For you
to have the machinery, there should be some demand. If you go on lobbying
just with senior bureaucrats, without any demand from the community, the
amended rules remain on paper.
Stjernswärd: I think we should remember the three Ts: ‘Things Take Time’
Although slow, progress is happening in timeless India. It is not only the
regulations that must be resolved, but also the price for the painkillers.
Uganda,125 as a model not only for Africa, has demonstrated that pain relief
costing hardly anything can be given freely provided you have the will and
enlightened political leadership. For most of the world, consideration of cost-
effectiveness is essential for covering pain relief to all in need of it. The poor are
the most cost-sensitive users of any health services, high cost reduces utilization
among the poor. Almost half of the world’s population, an estimated 2.8
billion, live on less than US$2 a day, and 1.2 billion live on less than US$1 a
day. In India, with one-sixth of the world’s population, 89 per cent live on less
than US$2 a day and 53 per cent on less than US$1 a day. WHO states that
there are affordable methods available for pain control that are maintainable at
community level. But when states or governments tender for morphine after
we have convinced them to introduce pain relief and palliative care, who pops
up? – the large multinational pharmaceutical companies. None offers
recommended generic immediate release (IRM) or slow release morphine
(SRM). These companies produce attractive didactic educational material for
pain relief. If they also would produce affordable generic morphine, like
aspirin, we could join forces, and change the world for the better, quicker. The
Keralaits solved the problem themselves by buying a used tablet-making
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machine from Amnedabad for US$12 and produced 10mg IRM tablets
costing around one US cent.
Parallel education – of the population and the health professional as done in
the Malappuram community approach – and making morphine available is
important and serves as a model for what to do for India’s 500-plus other
districts. Cipla Pharmaceuticals, India, has shaken the large multinational
companies by producing generic AIDS drugs accepted by WHO for US$320
instead of over US$10 000, and has created a centre for education in palliative
care in Pune, India, with 48 beds, and is also producing and using generic
SRM. Introducing palliative care education in the undergraduate curricula of
doctors and nurses would cost little but might have a big effect. Unfortunately,
there is only one medical college in Bangalore, St John’s, that has done it. It
will be important that availability of pain drugs is coordinated with the
educational efforts. Drug availability without adequate clinical empowering
education does not work, as we learnt at a visit to the main hospital in Gwálior,
India. Colleagues from the hospital claimed to be offering pain relief at a
meeting of the Indian Association of Palliative Care in that city in the mid-
1990s. The hospital had morphine donated by WHO and the Ministry of
Health. At a later inspection, we found that after one year of having morphine
only one patient could have been treated adequately, as the supply of morphine
was found intact, unused, except for a few tablets.
Bulgaria serves as an example where the pharmaceutical companies blocked the
development of a National Pain Programme achieving adequate pain coverage.
After a workshop there, David and I got the Ministry of Health to agree to
make pain drugs available as recommended by WHO, and to make palliative
care beds/units available in all the 13 cancer centres. Bulgaria had two trained
and devoted palliative care doctors, who should be ‘trainers of the future
trainers and palliative care doctors’. At a follow-up meeting in the capital,
Sofia, with representatives of the multinational companies present in the
country I pointed out that one month’s supply of their drugs would cost an
average of US$180 to US$200 a month. This should be seen in relation to a
doctor’s salary of US$105 per month and that it should be possible to achieve
the same pain control for a few dollars, if following WHO recommendations.
The Professor of Pharmacology enthusiastically offered to help the Ministry of
Health to make generic morphine available as recommended by WHO and I
sent him necessary background publications. What happened? A year later I
met the two doctors from Bulgaria at a workshop in Poznan [Poland] and they
happily informed me that SRM now was available free for the patients. It was
Innovation in Pain Management 
58
the same preparation [offered earlier] costing US$180 for a month’s supply.
Pointing out that ‘nothing is free’ and it probably was paid for by taxpayers’
money in a country whose health budget was already in the red, I wondered
what had happened with the professor’s recommendations? ‘Oh yes, he had
been in Germany for three months on a study trip paid for by the company
that sold the expensive non-generic SRM!’ There are still no palliative care
units in the 13 cancer centres or pain coverage. Human greed has to be
controlled before we can control pain.
Hunter: Briefly, I would like to touch on the issue of how the rate of spread of
a reform is often puzzlingly slow. This phenomenon was specifically addressed
by Professor Albert Dicey126 in 1905. He measured the time in years between,
say, the date when the fact that six-year olds hauled coal in mines became
known, and a law being passed to stop it. He measured this interval for many
different problems and established an average time interval of 25 years. This
was referred to as Dicey’s Law. 
I would also like to relate this whole question of pain to a wider social picture.
As a consultant physician in the Royal Shrewsbury Hospital, I was very
impressed that the Kerala Christian doctors there were good, very good, or
downright outstanding. I am intrigued by the fact that Christianity was
established in Kerala at an early date.127 The issue was raised by Professor Vere
earlier in this discussion, and I wonder whether there’s anything in the
mechanism of Christianity that explains why it appears to have these effects?
Clark: I think you have oversimplified it.
Kumar: Just one comment. The district of Malappuram where they are
experimenting with the neighbourhood network, with very good success, is 80
per cent Muslim.
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Twycross: I was going to make a similar observation. You cannot call Kerala a
Christian state. It may have 25 per cent of its population nominally Christian,
which is extraordinarily high for a country where the total Christian population
may be only 0.5–1.0 per cent. As far as I know there’s only one Christian state
in India and that’s Megalaya, up in the north-east where the majority of the
population would claim to be Christian, but certainly not Kerala. Kerala has
had a fascinating history. War created it in 1956, and it often has a communist
government. So you have to ask what is it in communism that fosters progress,
as well as in Christianity and Islam? And, let’s not forget the Hindus, of course.
Stjernswärd: West is not always best, nor is Christianity. The communism
referred to in Kerala is not of the Russian bureaucratic apparatchik type but
more of a true socialistic type, like, I dare say, the original Christian
communities. Furthermore, Kerala regularly changes governments, between a
more capitalistic and a communistic party, in itself a healthy phenomenon.
Kerala’s success stories are most likely founded on their high literacy rate, in
some districts up to 100 per cent, and that it is a matriarchal society in many
aspects. Kerala, like Sri Lanka, has an average life expectancy of 78 years and
the two societies are quite similar. Jimmy Grant, deceased Director General of
UNICEF, found that ‘quality of life’ measured by three things: percentage of
new born surviving, disease-free time during the time we have life on loan, and
adult mortality, how long we live. Sri Lanka beat many countries, including
several in the West. This is with an average income per family a year of around
US$300. Thus, money alone is not the solution.
What worries me is that palliative care is becoming overmedicalized. Since we
became humans in Africa during the Pleistonian time, some 1.8 million years
ago, we have died and had rituals and later religions with ceremonies that have
helped to cope with pain and suffering. I love Cecily’s concept of total pain and
have found that Buddhism and Hinduism, not only Christianity, have efficient
traditional ways to cope with spiritual and existential pain. They have
supportive rituals that they should not lose, like the secular agnostic Swedes
have done. ‘Inshallah’ is a wonderful word for accepting the unavoidable. The
Americans do not die, they just underachieve. The SUPPORT (Study to
Understand Prognoses and Preferences for Outcomes and Risks of Treatment)
study gives frightening data on a healthcare system that has gone amok, got
overmedicalized and commercialized.128 The cultural and socioeconomic
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factors are as important as the medical for what kind of supportive care and
death we get.
So, keep an open mind for multiethnic and cultural factors. Palliative care has
music therapy and visualizations, many countries that do not have pain relief
or palliative care have it too, but call it mantras or other things. We are born
and die in hospitals in the West and can spend months in the freezer in Sweden
before being buried, when other cultures require more civilized burial or
cremation within hours or a few days. We have lost the old rituals while others
still have them and find them supportive for bereavement and total pain.129
Vere: What I actually said was that I sensed that the aim to investigate and
improve the care of dying of patients was driven in part by Christian ethical
persuasion about the care of the person without obliterating their personality.
May I just ask a question about Figure 6 [see page 51] that is very helpful? Why
has the use of morphine declined in the UK? Not horrendously, but about a
50 per cent [decline] over a period which is quite brief [1993 to 1996], at the
very time that you might expect it to stay up.
Joranson: First of all, those statistics are reported by individual governments,
as to the amounts of each of the drugs that were consumed. Consumed means
the amounts that are distributed to the retail level. Over time that typically
equals how much is consumed by patients, but it’s more a measure of
distribution to the retail level, than it is to individual patients. Having said
that, I would speculate about why there was a sudden drop and apparently a
consistent pattern afterwards for morphine in the UK, and that might have to
do with the introduction of other opioids at the time.
Twycross: If you look at it from a distribution point of view, before that
strange peak [in 1994] there is a dip. Presumably, for one reason or another,
people ran down their stocks and then suddenly built them up again. So you
have to iron out those two years. They kept the stocks up for a couple of years
and, then again, they found they were overstocked, and there is another
consequential dip. I agree with you that since then it may be because of other
opioids on the market.
Bond: If I could say, Chairman, that we have concentrated very much until
just recently on the white Anglo-Saxon view of life in pain and I think the most
recent speakers have brought out the fact that life is not exactly the same in
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other parts of the world as it is here. Perhaps the best way of dealing with the
pain problem in a country that is not ours is to start at the bottom, and find out
what it is that people complain of and what it is they already do, because they
might be pretty efficient, not be like the Christian missionaries of the nineteenth
century who went in and said, ‘This is what you need’. You have to go and find
out what they think they need and see what we can do to help them. 
A little anecdote might not go amiss, just to show how very difficult it is to
understand other cultures sometimes. This is a story about a young man who
came from a north African country to Holland and reported to his family
doctor with abdominal pain. The family doctor was not able to find any
physical cause for it, and asked the young man if he could think of any reason
why he should have abdominal pain. The young man said, ‘Well, of course, I
came over here to earn money to send back to my family and I am afraid I
haven’t been sending back as much as I should have done’. So the doctor said,
‘So, do you think that’s why you have got abdominal pain?’ He said, ‘Well, I
know my father’s angry with me’. The doctors asked if that was likely to give
him abdominal pain. He said, ‘Oh yes, that’s quite possible, in fact I am sure
that’s the real reason, because my father has got pain in his knee’. So the doctor
then said, ‘Well, if your father’s got pains in his knee, why should that be?’ And
the young man replied, ‘Well, in my country when girls are born they are of
no consequence, compared with boys, so boys always sit on the father’s knee as
a baby, and if the father later is displeased with the boy, he gets pain in his
knee. Symbolic, you see’. So the doctor said to him, ‘Well, why don’t you go
back and make your peace with your father and help to get rid of his pain in
his knee and the pain in your stomach?’ The boy replied, ‘Well, I am a bit
loathe to do that, because I will become impotent’. So the doctor asked, ‘Well,
why will you become impotent?’ He said, ‘Well, if a father is very angry with
a son, the son always becomes impotent’. So there you are, we have to be very
careful when dealing with people who are not in their own society.
Clark: Thank you for that anecdote. Sri Lanka has been mentioned by Dr
Swerdlow and Professor Stjernswärd, and as some of you here may know I have
spent some time to my great pleasure and privilege reading the letters of Dame
Cicely Saunders in depth in recent years,130 and in that correspondence I
discovered a relationship between Dr Saunders and Dr K J Rustomjee of what
was then Ceylon [now Sri Lanka], who visited you [Saunders] in 1961. Can
you tell us a bit about that?
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Saunders: This large and splendid gentleman arrived at St Joseph’s and said he
was interested in starting a home for cancer patients. How he knew about St
Joseph’s I really don’t know, but he had been in the USA and he certainly
introduced me to the American Cancer Society, who were a great help when I
went over in 1963. But I just remember him as a splendid chap whom I have
kept in correspondence with, but we were obviously in some way or other on
the same wavelength, although we came from such very different places. What
we were aiming to do was something remarkably similar, and he got there first.
Clark: With the Bandaranaike Memorial Home,131 which opened in 1962.
Well, we have had a fascinating international interlude, rather unusual for
Anglo-Saxons to look beyond their shores for quite as long as this, more than
an hour, indeed. We have a little time now for any final observations or
questions of any kind.
Swerdlow: Just a quick one to follow up Sir Michael [Bond]. I went to one of
the most extraordinary medical pain congresses I have ever been to in Japan.
Half of the speakers were Westerners and the other half were Japanese. The
Westerners all talked about their way of relieving pain and then came the
Japanese who produced lots of beautiful slides, pictures of herbs growing in the
garden,132 that sort of thing, and then their results. And their results were very
different from ours. I am not quite sure why, whether this was a question of
their mathematics or whether they were very pleased with themselves, but it
was interesting to see the difference.
Vere: I don’t think we have said much about other ways of prolonging drug
action and have focused a great deal on the short-acting drugs. I thought it
might be right to mention Dr Martin Wright’s contribution at the Medical
Research Council, who not only designed the peak flow meter, which made it
possible for us to measure respiratory depression in some ways, but also
designed the syringe driver pump, which has made such a difference to
continuous pain control,133 and one can certainly remember what a splendid
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thing it was to see patients at Northwick Park, for example, who had been out
shopping that day, who had had a metastasised tumour for two years with
severe pain, and had continuous diamorphine treatment for two years, with a
syringe driver pump, going about their daily business. 
The other thing is that the drug one would naturally have thought of early on
was methadone, and it was Dr Twycross who made the first observations about
what happened if you did give methadone to patients for this indication and
showed that it in fact shortened their life in a measure.134 Now that was not
expected and I think it wasn’t because we hadn’t been appraised sufficiently of
the three-step half life of methadone, which was shown by Inturrisi and
Verebely quite a few years before,135 though to be fair the third step in the half
life was shown around the time when the clinical trials were being done. 
Clark: Are you saying that was a candidate drug for the slow-release formulation?
Vere: Well, yes, and what was very amusing about it was that a well-known
pharmaceutical company came to see us that very year to say that they were
thinking of developing a sustained-release opiate preparation, and I
remember saying to them – and I think Robert [Twycross] had the same
conversation with them around the same time – ‘What are you putting in it?’
And they said methadone and I said, ‘For goodness sake, don’t do that’
(because of Robert’s work), and they said, ‘Well, what should we put in?’ I
said, ‘What about morphine? It’s a sustained-release preparation, [and] this
will make morphine available in a sustained-release way.’ I think Robert
advised them in exactly the same manner. They then produced MST.136 It’s
interesting how these things happen.
Main: We have had a lot of discussion about cancer pain and of course it is of
terrific and profound importance, but I do just want to redress the balance a
little and talk about non-cancer pain. I think the way people have thought
about how we should approach the treatment and management of non-cancer
pain has changed quite a lot during the last century. In particular, how people
have understood the relationship between pain and suffering and what our
objectives of assessment and intervention should be. The Clinical Standards
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Advisory Group (CSAG) report137 emphasized that pain and disability needs to
be understood from a societal as well as individual perspective and that there
have been significant changes in public perception of what we ought to do
about pain in the context of disability. 
There is a significant group of patients who are extremely disabled, a
proportion of them as a consequence of ill-advised clinical decisions, but I
think in understanding pain from a societal perspective we have got to
understand that individuals cope with pain in many different ways. And
indeed if we look at the epidemiology we will see that there are a lot of patients
in the community who do not consult their GPs with pain at all. Indeed, one
of the best ways of managing non-cancer pain is to change what you do. The
trouble is if what you decide to do is to lie down all the time and do nothing,
the cost is too high. I should like, therefore, to broaden the discussion to
include pain associated with suffering and disability, because I think in terms
of a comprehensive way of looking at pain, we have to move beyond the
symptom of the pain itself. It seems sometimes when we talk about pain we are
talking about it as if it were a physical sign, but of course this is incorrect. Pain
is a physical symptom that is multi-determined and I think we have focused
too much on the ‘sign’ at the expense of the ‘symptom’ this afternoon.
Joranson: Two brief comments on the question of methodologies for achieving
changes in public health policy that are necessary to implement the WHO
guidelines. The first is that since the WHO guidelines recommended that
opioids such as morphine be available in every country,138 now there need to be
guidelines about how to evaluate the national policies that govern opioids in
every country. Such guidelines have been produced by WHO,139 and are listed
on the bibliography that I handed out.140 They provide a book-end to the
earlier 1986 WHO guidelines, where 14 years later in 2000, there are
guidelines for evaluating any national narcotics control policy, to see if it is
‘balanced’, that is to say, does a national policy have the provisions necessary
to ensure the availability of opioid analgesics for pain relief when needed. It’s
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a part of a treaty to which most countries are party. The second point is that
in the evaluation and addressing of barriers to pain relief, whether it be for
opioids or not, we have always found the model established by Everett Rogers,
who has written a series of excellent communications and social policy studies
from around the world that shed great light on how change occurs.141
Saunders: Just going back to the Japanese research described earlier. There’s a
Japanese man who wrote a book on dying in Japanese hospitals, translated into
English, and which was a best seller,142 and it’s really quite a horrific thing. He
was completely moved by reading Elisabeth Kübler-Ross’s book143 and has
turned into a hospice doctor. He took me round his hospice in Tokyo and I
don’t know what drugs he was using, but what he describes at the end of his
book, we are talking about beautiful surroundings and so on for dying, but
what really matters is the relationships and there was no doubt at all that the
relationships between that man and his patients were a major part of the pain
relief that they were obviously experiencing. 
Stjernswärd: May I just ask a question, with so much expertise around? What is
the total size of the problem, estimated number of sufferers needing palliative
care and how will we be able to cover the need? The hospices alone will certainly
not be able to cover all, nor an institutionalized governmental approach. Giving
figures for the need and pointing out that there are relatively simple and
affordable solutions will be a strategy for achieving commitments to implement
pain relief and palliative care, not only for cancer patients, but also the terminally
ill in chronic diseases, AIDS and those with neurological diseases. For the
chapter to the next edition of the Oxford Textbook of Palliative Medicine144 that I
am writing with David Clark, I have used as a rule of thumb: the global deaths
and for estimating the need of different countries I have used their death rates,
estimating that 60 per cent of those will need pain relief and palliative care.
Considering that most cancer and AIDS patients will need it and data show that
pain is one of the most common symptoms together with fatigue in the
terminally ill, that 60 per cent may be an underestimate than overestimate. With
56 million deaths a year there will be 33 million needing pain relief and palliative
care. Underestimating that at least two care-giving persons, usually family
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members, also will benefit, this gives a figure of 100 million people a year who
could receive an improved ‘quality of life and death’ if palliative care could be
offered. These figures also indicate it is a public health problem worthy of attack
and the necessity for a public health approach. If anyone present today can give
me another figure than the 60 per cent used it would be appreciated.
When advocating and getting commitments for establishing and planning
national palliative care initiatives, the use of the death rates for estimating the need
for palliative care has served the purpose well, such as in Uganda and Jordan.145
With the future age distribution, age pyramids, and the compressed ageing, we
are healthy up to a late age, but then there is an explosive need for palliative
care. The future looks grim, as from earlier figures there are four to 12 care-
givers per care-taker, and these figures soon will be in a ratio of around two or
fewer givers to one taker. This also will mean the number of taxpayers per
recipient will be fewer. Will the working young be willing and able to cover
palliative care as we see it when practised optimally in the hospices today for
the elderly in the future?
Twycross: I share Chris Main’s concern about the bias in the afternoon’s
proceedings and I fear that the written version will be a very lop-sided view of
innovations in pain management during the twentieth century. But I guess we
couldn’t hope to have been comprehensive.146 So I am going to continue the
bias. I think you know there are a lot of good things on the horizon. You know
that 30 years ago, even 20 years ago, progress certainly in relation to drug
therapy was largely serendipitous. We had morphine and aspirin, and a few
related drugs, but with all the adjuvant analgesics, it was serendipity that got
us on to their track, and research grew from serendipitous observations. But,
now in pain management, the research is being driven by a much more
profound understanding of the underlying mechanisms. It is truly remarkable
what people like Tony Dickenson and other more basic pain researchers know.
In ten years’ time the whole drug therapy may well have changed. Certainly it
will be dramatically broadened, widened and deepened. That’s because in the
last five to ten years research has increasingly been driven by basic scientific
knowledge, and not serendipity. 
147 Melzack and Wall (1965). See Appendix 1, pages 73–82.
148 See, for example, Williams et al. (1993).
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Bond: Could I do what Robert didn’t and that is to support what Chris Main
said and just say a little bit about the other side, because what Robert said is
absolutely right. The work done by Pat Wall and Ron Melzack in 1965147 was in
fact well grounded on existing research. Willem Noordenbos had even suggested
the existence of the gate mechanism, but he hadn’t demonstrated it in the way
that Pat and Ron did. And since their time in 1965, there has been an explosion
of biological research. I entirely agree with Robert’s comments. The picture in
psychology is actually rather different, because up to the middle of the twentieth
century the psychological approaches were based mostly on psychoanalytic
theory and on psychosomatic theory, which were not very helpful for either the
understanding of chronic pain or the management of chronic pain problems. It
was of some help, but not as much as one might have imagined. 
And then in the 1960–70 era a profound change occurred in that approach to
pain management with the appearance, first of behaviour theory, and more
recently of cognitive theory, so that we got the cognitive behavioural
approach,148 which has been amplified in various ways as we have come to
understand through research more and more about the psychological side of
pain and suffering. I think Descartes might have been proud of the way we
have conducted ourselves today, because it seems as though there is still only
one aspect of pain and that is the biological one. But everyone in the room of
course, in reality I don’t think they would, shares the view that we have to use
a bio-psycho-social model, which is something that appeared just a few years
ago to encompass totality and it also includes a spiritual dimension amongst
others. So I think that if we are going to present ourselves as real pain experts
we cannot leave out of this discussion the contributions made towards pain
management, whether it be in pain due to cancer, and whether it be in pain in
non-cancer conditions, but I think a substantial expansion in the knowledge
of the psychological and social aspects of pain itself.
Professor John Walker-Smith: As a paediatrician, could I just say a few words
about pain in neonates? It is astonishing that in the past neonates were not
believed to suffer from pain in the way older children did. I remember, as a
young doctor in Sydney [Australia] in the 1960s, performing routine
circumcision of neonatal boys. At that time all Australian boys were routinely
149 Walker-Smith (2003). See Williamson and Williamson (1983); Anand et al. (1987).
150 For WHO three-step pain ladder, see Figure 5, page 43.
151 Duragesic patch (Fentanyl transdermal system, Janssen Pharmaceutica Products). See also
Appendix 2, note 186.
152 Immediate-release and slow-release morphine.
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circumcised unless there was a parental objection. The poor little fellows would
scream in pain. It was assumed that babies didn’t experience pain. In 1983 it was
shown that physiological stress was reduced by local anaesthesia in children being
circumcised, but it was not until neonatologists demonstrated hormonal and
metabolic responses to surgery with or without narcotic analgesics, that proof
was provided that neonates reacted adversely to painful stress.149 This occurred
quite recently. It is astonishing that we were so terribly ignorant in the past. 
Dr Jeremy Johnson: Just a very brief comment. Quite rightly looking forward
to pain relief, locally and globally, mention has been made of research, but
there’s also the delivery of the molecules to where it matters in terms of the
need. And there’s also been mention of inappropriate use, particularly of
methadone and fentanyl. Is there a feeling that perhaps the pharmaceutical
industry might in fact highjack some of the work of WHO?
Stjernswärd: The large multinational drug companies are already doing it,
ruthlessly caring for their profits, single-eyed, introducing unaffordable but not
better or needed new drugs through aggressive unethical marketing while
refusing to provide affordable generic versions allowing a meaningful coverage.
Together with bought-up or naive colleagues they do a lot of intellectually
seducing masturbation on the WHO pain ladder.150 This gives a false
impression of credibility but facilitates the marketing of their products. As
mentioned earlier, as soon as we, with lot of efforts, have paved the way for
efficient pain relief, the industry comes in and takes the market with drugs not
recommended, thus making the initiatives non-sustainable. In Syria, for
example, one big multinational company that knew I was coming even sent
beautiful representatives from a neighbouring country to see leading key
clinicians with their information materials, free samples and even establishing
‘research trials’ with their fentanyl plasters151 in the leading cancer centre two
weeks before our Ministry of Health workshop. It was obvious that lot of
misinformation on how bad IRM and SRM152 were had been given to the local
‘pain expert’ in the centre, or he was simply stupid or opportunistic in his
statements. One week after the workshop the company held a ‘scientific
seminar’ in the cancer centre. Even the USA has difficulty affording the new
expensive drugs, where another company aggressively markets a new drug that
earns it US$1.8 billion a year, while due to this marketing the drugs are being
over-used by non-chronic pain patients and where addiction may become a
problem.153 In Malaysia, we had a national workshop in the early 1990s. I
learnt there that they had non-generic expensive MST available, which they
did not when we planned the workshop. Six months earlier the same company
mentioned above had visited the leading cancer specialist who then
approached the Chief Pharmacist and pledged the need for pain relief drugs
according to WHO recommendations. 
The tobacco industry had similar approaches when, as cancer chief of WHO,
I addressed tobacco control and cancer prevention at big international
conferences. Usually after my lectures a guy stood up claiming that pollution
and other substances caused more lung cancers than tobacco, so why was I
bothered? Asking the person to identify himself, the answer usually was ‘I am
a consultant’ or ‘a researcher’. When asked from where, it was clear that he was
from the tobacco industry. Finito comedia! 
Hunter: Has anybody in the audience had any experience of working with the
City of London Migraine Clinic? Because the treatment of that particular kind of
headache was very significantly improved by research done by its Director, Dr
Marcia Wilkinson. She discovered that the nausea of migraine significantly slowed
down and impaired the absorption of oral paracetamol and that this problem was
eliminated by giving oral metoclopramide 15 minutes before the paracetamol.154
Clark: Seemingly not. Can we have a comment to finish on rather than a question?
Vere: I am aware of this clinic, I have worked with some of the people in it
and, yes, what you say is true. There was a very bright observation made and
some good research done about it. But again, I think migraine is an example
of a pain syndrome and a situation where people have taken, particularly the
industry, far too narrow a view. And it was the lateral thinking that went on at
the Bart’s clinic and there’s a need for a lot more.
Clark: I would hate to be the cause of migraine among those assembled here. Dr
Saunders pointed out to me earlier that alcohol is an excellent drug and hasn’t
been mentioned yet. We are coming bang up to our time. When we spend four
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hours together discussing a subject and in the last 15 minutes strong words come
forward about how imbalanced that discussion has been, that to me is the
outcome of a good afternoon. And probably suggests that this was ‘Innovations
in Pain Management I’, and that even now the sequel is being prepared. 
I would like to thank Tilli Tansey and her colleagues for the organization, the
Wellcome Trust for its funding support, Marcia Meldrum for her
introduction, the American Pain Society for financial assistance with travel
and most of all to thank all of you for contributing to what I believe has been
a fascinating afternoon. Thank you very much indeed.
Dr Tilli Tansey: May I add my comments to those of the Chairman? Thanks
to all of you who have travelled here to contribute to this afternoon. I would
like to add, in view of Dr Twycross’s concern, that this is not going to be the
recent history of pain management, but a contribution towards that, and I
thank you all very much for contributing to the proceedings of this afternoon. 
So may I thank our Chairman, David Clark, for the excellent chairing of this
meeting and I hope you will join me in thanking him. This meeting has been
recorded, and we will be preparing a transcript for publication. 
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Appendix 1
Extract from an annotated Physiological Society interview
with Professor Patrick Wall (1925–2001)
by Dr Martin Rosenberg and Professor Steve McMahon on 5 February 1999 155
Professor Pat Wall: The first question that interested me was connectivity in
the nervous system. I should say that in Oxford at that time Sir Charles
Sherrington was still alive and the nervous system was really the only subject
to work on and in fact the spinal cord was the only get-at-able bit. But the
major issue of the time was connectivity and in terms of anatomy the question
was, how did you find out if one place was connected to another?
Paul Glees156 had invented a silver-staining method in which you could just
about see degenerating terminal arborizations. You saw a series of dots in the
area of terminal arborization. That was what I did as an undergraduate with
Glees and that was why I got my first job at Yale with Fulton in 1948. Fulton
was American but had been in Oxford, first as a Rhodes scholar and then with
the Sherrington group in the 1920s. John Eccles had been his graduate
student. Yale had gone through a revolution in the late 1920s, in which they
decided to make themselves into a proper medical school and they had called
in all sorts of people, including Fulton who was brought back from Oxford to
set up physiology at Yale in 1929.
It was 1948, when I was 23. Thanks to the war, everything had been
wonderfully speeded up so that one could get a label of a medical degree very
quickly. Then because of my work with Glees, I was picked up by Fulton and
went to physiology at Yale on to this frontal lobe project: very classical
stimulation of cortex, looking to see changes, and lesions in cortex and looking
for anatomical changes. What I did then was to look for autonomic changes as
a result of cortical stimulation and first found that in fact autonomic responses
were very widespread and that was because in monkeys the fifth nerve
innervates the skin and you can get autonomic changes because you are
155 The full transcript of this interview will be deposited in the Archives of the Physiological Society,
SA/PHY, held in Archives and Manuscripts, Wellcome Library, London.
156 Glees (1946); Marsland et al. (1954). This silver method was developed for the study of normal
and degenerating synaptic boutons and demonstrates neurofibrils, but obscures axons and terminals.
stimulating the fifth nerve. But when you cut the fifth nerve you can then see
the true cortical systems. So it was immediately apparent that the motor cortex
produced autonomic changes…in blood pressure, heart rate, respiration
changes and then we rapidly found that there was a strip of cortex which starts
in the cingulate cortex, goes forwards and over the supra-orbital cortex and
then continues extending laterally to the insula. So we described this as an
autonomic response area for the first time,157 although Papez158 had described
it before. I then set about finding out the anatomy. 
I was at Yale for two years to 1950, by which time because of my attack on
strychnine neuronography I had been picked up by Warren McCulloch, at that
time in Chicago, at the University of Illinois, cooperating with two absolute
geniuses, Walter Pitts, a mathematician, and Jerome Lettvin,159 a
neuropsychiatrist who had turned to physiology. McCulloch and Pitts had
already started neuron modelling, so the Pitts–McCulloch neuron is still the
basis of many of the neuron models.160
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Figure 9: Professor
Pat Wall.
McCulloch organized for me to get the job of assistant professor at the
University of Chicago in anatomy. Lettvin was a technical genius, and had
really spotted the possibilities for electrophysiology, who had set up his own lab
in a lunatic asylum, called Manteno State Hospital, a gigantic state hospital
about 50 miles south of Chicago. 
David Lloyd and John Eccles had defined circuitry within the cord: polysynaptic,
monosynaptic reflexes and descending controls.161 So we set about first doing very
classical recordings, mass recordings. Pitts, who was very strongly in with Norbert
Wiener at MIT, had become fascinated with the nervous system. Wiener’s
Cybernetics was actually written largely by Pitts. The next stage of the story is why
we four migrated in 1953 to MIT at the invitation of Wiener. We were going to
explain the nervous system in the ways that Wiener knew it worked.
There were some technical abilities that hadn’t appeared at that time, that is to
say to do with the electronics. At Chicago, Ralph Gerard had made the first
microelectrode and in order to use the microelectrodes you had to know about
grid currents.162 All this became very, very simple as transistors appeared in the
late-1950s, which had electronic valves. By the mid-1950s, people began not
just to record mass potentials, which had obviously been done for a very long
time, but to record single-unit potentials, and to make various types of metal
microelectrodes. So it was an exciting time because the technical possibilities
had suddenly hugely exploded.
We moved in 1953 to MIT which was fantastic in terms of technical support,
because they’d been the major developers of radar. We were in the research lab
of electronics. There were computers, of course, but they were very
cumbersome things. MIT had a group of ‘calculating women’. It was an
astonishing sight, a room of at least 40 women, calculating collision tracks, and
a lot of cosmic ray data on hand calculators. It was possible for us to make
multi-channel recordings in the spinal cord of point variations and to give
these ladies the numbers and they would hand calculate the interpolations and
maps, field potentials and source–sink maps.163
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page 105.
163 For the procedures used at the time in making these maps, see Howland et al. (1955). For a
discussion of volume source and volume conductor, see http://butler.cc.tut.fi/~malmivuo/
bem/bembook/07/07.htm (visited 29 June 2004).
Claude Shannon was there, having started at Bell Telephones, simply looking
at information theory, which again was really an anti-noise strategy.164 These
exceedingly practical engineers, physicists, electronic engineers, were
fascinated with the brain. Somehow the brain was doing what they would like
to do. They had set us up all in this electronics laboratory, mainly militarily
supported, but no secrecy at all. There were secret projects going on, but they
were completely divided and separated and funded separately.
We were regarded as the group who was going to lay golden eggs, but you
could chivvy the goose. There was a sense – particularly by people like Wiener
– of huge confidence that he knew now the methodology by which you could
understand complex circuits. It was then our job to prove him right, or that
was his idea. Wiener was a great, massive, self-obsessed, manic genius. This was
a difficult time but impressive people like Jerry Wiesner,165 who was the boss
of the whole thing, an electronic engineer who had been involved with radar
and an absolutely brilliant organizer, protected us from this crazy man.
The important thing that Pitt, Lettvin and I did was to do a source–sink
analysis of the input to the spinal cord, to try and follow a volley through the
spinal cord from dorsal root to ventral root. Then we manipulated it by
inhibiting the reflex and remapping. The results were very startling, to show
an inhibition precisely where it was happening and as far as we could see
happening presynaptically. We came out with a new method that involved
calculation, the understanding of the second differentials and you can imagine
that that was enough for most physiologists and for most people. …We said
that you could inhibit an impulse presynaptically, which everybody knew was
absolute nonsense and impossible. However, we published these maps and
these conclusions in the Journal of Neurophysiology in 1955.166
I went to the 1953 International Physiological Congress in Montreal and gave
these results. I was summoned to what consisted of a star chamber of Wilder
Penfield, who was the head of neurosurgery in Montreal, E D Adrian, John
Eccles, and Herbert Jasper, the electrophysiologist with the Montreal
Neurological Institute, who was on his home territory. They called me in, just
the four of them, to Penfield’s office and said, ‘Would you explain to us what
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you have been saying?’ So I gave them a sort of five-minute summary and they
then said right out in the open, ‘Look here, Wall, you are obviously a smart
guy, you have been to the right places, but you are in the wrong company. This
is simply impossible. This is some sort of artefact you are wasting your time
on. Goodbye’. That really was something as you can imagine. Eccles was the
strong one in that meeting. I thought, ‘My God, if those characters are going
to tell you that this is nothing more than an artefact as a result of using
electrical stimulae’, and so on. So in fact we backed off.
There was a question, ‘Is there some other way in which you could follow the
passage of nerve impulses, other than mass recording?’ There was also the
problem at that time that nobody was successfully recording from small cells
and certainly not from small axons. It was just on the edge of being possible.
Lettvin went off looking at small axons and started on the optic nerve of the
frog, and out of that came Lettvin and Maturana, ‘What the frog’s eye tells the
frog’s brain’.167
I thought of another method, because I was impressed by Katz and Schmidt who
had shown that if you took one group of active nerve fibres, and looked very
carefully at the threshold of its neighbours, as the volley went by in one group you
could see there was this slight shift as a result of the field spread in the other fibres.
I thought, ‘Here’s a way in which we could see whether impulses have passed in one
group of nerve fibres. We’ll test the threshold of another group of nerve fibres’. So
that’s what I thought I was going to do, but what happened, of course, was that I
then saw huge threshold changes as a result of presynaptic depolarizations.
At that time it [pain] was all to do with Sherrington, Eccles, Lloyd and reflex
circuits which were a physiological event, not anything to do with behaviour or
sensation. Eccles having said that this was all an artefact, then took up my
technique and it suddenly became the popular, accepted technique. At first Eccles
needed a technique that he could use which was microelectrode stimulation in
order to find the threshold shift of terminal arborizations. So he became extremely
complimentary of me, never gave me any credit, but complimentary, and he
proposed that I must come to Canberra, which I happily resisted. 
So then here in the spinal cord, and I could see these threshold shifts all being
done with relatively large metal microelectrodes, but the circuitry had
improved and now I could use real microelectrodes and I shifted to glass
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potassium chloride-filled microelectrodes. Then I could easily see single units.
And so then I started recording single units in the dorsal horn168 and first of all
classified what the cells did, and it was at that stage that the question of pain
arose, because I went naturally on to a search for cells which would only
respond to intense stimuli [natural stimuli and/or electrical stimuli] and I
simply couldn’t find them and I still haven’t seen one really.
By that time E D Adrian, Ynge Zotterman, and Peter Bishop had decided that
there were modality-specific peripheral nerve fibres and therefore it was
extremely natural to expect modality-specific cells, relay cells, in the spinal
cord.169 They thought I was somehow missing the point. I could find cells that
only responded to low-threshold afferents, that was clear, touch cells, but I
simply couldn’t find these nociceptive specific cells. 
Don’t forget that inhibition or mixtures of stimuli was also very classical. That
…had been set up certainly by Lloyd and Eccles and it was exactly what they
were doing as was Lundberg [defining the flexor reflex].
I found one inhibition which actually came from an accidental personal
observation. When pushing a hand-pushed motor mower with a hellish
vibration, I began to realize that after enough vibration, my hands were really
remarkably numb, and I thought, ‘Well, let’s try that on a cat.’ So Cronly-
Dillon and I published on the fact that vibration outside the receptive field of
a cell would inhibit it. That was the first trigger for the gate control.170
Ron Melzack happened to be in psychology at MIT at that time and
psychology at MIT at that time was at a very low level. It was in fact in the
business school. But Ron had worked with Livingston171 who was interested in
pain and had raised puppies in isolation and said they took some time to
develop pain. Melzack had done work in Oregon, so he was interested in the
physiology of pain and we just started talking together and put together
everything we knew at that time. This was all talk, but it was partly his
Innovation in Pain Management – Appendix 1
78
168 Wall (1973).
169 See, for example, Adrian (1928); Wolstenholme and O’Connor (eds) (1959); Bishop (1989). For
Peter Bishop’s work on how the brain sees objects, see www.science.org.au/scientists/pb.htm (visited
28 June 2004).
170 See Figure 9 and page 37.
171 Professor William K Livingston was head of the Department of Surgery at the University of
Oregon at that time. For background details, see Livingston (1998). 
experimental work and a lot was my experimental work. Melzack did mainly
behavioural experiments, but some electrophysiological.172
It’s interesting that we wrote two major articles, one published in Brain,173
describing our views on gate control. It had no effect at all. ‘Gate control’ was used,
I think, for the Science article, the one that is always quoted.174 And we had in fact
been swapping our names backwards and forwards, some were Wall and Melzack
and some were Melzack and Wall, it happened to be his turn to be first. 
I drew that goddamn diagram. We first thought of it as ‘gate control’
…because we were always using triode valves which had a gate. That was my
meaning of the word ‘gate’. We’d been struggling with gate currents and used
a gate control all the time for varying amplification. In that diagram which is
an absolute minimum diagram, I’d introduced the smallest number of possible
components, and some pure guesswork, like the fact that the proposal that the
substantia gelatinosa was the origin of the inhibitory control. We already knew,
and this again goes way back, that there were descending controls. It really goes
back to Sir Charles Sherrington, who knew that a decerebrate animal had
conspicuous proprioceptive reflexes. If you spinalize the decerebrate animal,
the cutaneous reflexes dominate. So we knew that cutting the spinal cord
released the cutaneous reflexes so we could install in the gate control, a
descending control, on to a local circuit, which was being affected by the type
of impulses that came in and the activity of the local cells.
The original paper explained that the diagram was a cartoon [Figure 10].
…That diagram is run entirely by presynaptic control and we knew at the time
there were also postsynaptic inhibitions – it said so in the paper – but it was
always a squabbling.
The previous joint papers hadn’t been related to pain, but to all sensory inputs,
which I still think is the case, and we decided, ‘OK, just let’s talk about pain
in the 1965 Science paper.’ But there was antagonism from the physiologists,
…Adrian and Zotterman and Perl.175 So the dictum of the physiologists was
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very, very strong in favour of specific transmission and here was a challenge to
them, which made them very, very annoyed. 
Two things happened: one was that I could already see this powerful inhibition
produced by low level inputs, so immediately we started trying it on ourselves,
we made up simple stimulating gadgets to stimulate peripheral nerves, and
then I went to W H Sweet, who was the head of neurosurgery at Massachusetts
General Hospital at Harvard, and we tried on ourselves and then we tried on
patients and came up with TENS [transcutaneous electrical nerve stimulation]
and a paper called ‘temporary abolition of pain in man’.176 Now that of course
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Figure 10: Cross-sectional representation of posterior dorsal horn of the spinal cord, showing
the main components of the cutaneous afferent system in the upper dorsal horn.The large-
diameter cutaneous peripheral fibres are represented by thick lines running from the dorsal
root and terminating in the region of the substantia gelatinosa; one of these, as shown, sends a
branch toward the brain in the dorsal column.The finer peripheral fibres are represented by
dashes running directly into the substantia gelatinosa.The large cells, on which cutaneous
afferent nerves terminate, are shown as large black spheres with their dendrites extending
into the substantia gelatinosa and their axons projecting deeper into the dorsal horn.The open
circles represent the cells of the substantia gelatinosa.The axons (not shown) of these cells
connect them to one another and also run in the Lissauer tract (LT, shaded to distinguish it
from the substantia gelatinosa) to distant parts of the substantia gelatinosa. From Wall (1964).
Adapted from Science, 1965, 150: 974.
was then a very difficult challenge for a physiologist to dismiss, since it
worked, and furthermore it recruited the clinicians. So the clinicians
immediately leapt on this as an explanation for the various hyperpathic states
and so on. The anaesthetists caught on very rapidly indeed. Willem
Noordenbos was an important ally from the clinical world and it spread, but
surprisingly slowly.177 As a matter of fact, in the citation index it eventually
became a Citation Classic, and they wrote an article on this, pointing out this
was a highly unusual paper, that usually a paper comes out and is cited
essentially immediately, the highest citation is within the first year and then
it peters off. This one took something like five years before people were
beginning to cite it and that was this whole recruitment, not of physiologists,
but of the clinicians, pharmacologists, and so on.178
Zotterman, for example, had wondered what scratching was about and so he
recognized ‘why do you itch?’ It’s because itch fibres are excited, that’s
according to Zotterman, but how and why does scratching then work?179 There
must be an inhibitory process somewhere. Livingston and Noordenbos, as
clinicians, had said, ‘Look here, there must be central interactions to produce
what we see in the patients’. I then had some very good students, Mendell for
example,180 and we …showed ‘wind up’,181 so then we got into facilitation as
well as inhibition.
I was really interested in the basic fundamental properties, almost on a cellular
level, but it turned out that it was relevant to pain processes. That’s a different
story, which starts almost 25 years back, but really in 1973 or so. I realized that
the reverberations of this were going through the pain field. I had a huge ally
and that was John Bonica in Seattle, who was a great organizer, a great
character, almost pure clinician, who invented the thought that pain was a
special problem, a clinical problem, that it needed lots of experts focusing in
[on it], even on an individual patient. First he set up his own clinic in this
cooperative way in Seattle in 1947 and then wanted to expand it. 
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There’s a practical reason for pain clinics in hospitals and that is that the
anaesthetists decided that people could not get their Fellowship of the Royal
College of Anaesthetists (FRCA) until they had done x months in a pain clinic,
so no training hospital can be a training hospital, unless it’s got a pain clinic.
Now it is true that that idea came certainly from Bonica, with me encouraging,
obviously. I think it remains in doubt whether this is the right approach and
whether what actually happens in a pain clinic is what is supposed to happen.
You know 60 per cent of the pain clinics here have only a single consultant in
one subject, well, that’s instantly against the ideal.
I was always affected by C Judson Herrick, who said if you want to succeed in
science, you must do three things: first, find something nobody else is working
on, and he found the brain of the tiger salamander; second, write a book about
it, so he wrote a book called The Brain of the Tiger Salamander, which is a very
important book, the beginning of detailed comparative neuroanatomy;182 and
third, start a journal and he started the Journal of Comparative Neurology. So I
followed his advice. Nobody was working on pain, because it was simply
completely understood and there was no point in working on it. Melzack and
I had written a Penguin, so the book was there.183 We then decided to write
The Textbook of Pain. Publishers told us that pain was not a subject. They had
their boards of advisers who said, ‘It’s ridiculous, it’s just not a subject’.
Eventually Churchill Livingstone agreed to publish it and, to their absolute
astonishment, it was a huge success.184 While Bonica was setting up the
International Association for the Study of Pain, the IASP, I said, ‘Right, here is
a chance to start a journal’, because I still thought that this is an orphan
journal, nobody is going to buy it, we need a society whose members will
automatically buy it. So Bonica and I were in agreement and …this year
[1999] is the 25th anniversary of that journal, Pain.
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Morphine has been scientifically proven to be the single most effective opioid
to achieve both immediate and long-term control of pain, and to manage
breakthrough and procedural pain in either oral or parenteral formats. It has a
very low incidence of adverse effects and less than 0.1 per cent of patients who
use morphine to control pain ever go on to misuse it.
Oral morphine has been shown to control more than 90 per cent of patients’
chronic pain. Injections or infusions of parenteral morphine are only needed
to control 3–5 per cent of patients with difficult-to-control chronic pain
syndromes.
In contrast, more expensive preparations of other opioids, such as transdermal
fentanyl:
• do not add any increased potential for benefit;
• may have a much greater risk of misuse on the black market 
(they are both chewed, and the gel dissolved and injected);
• may be more difficult to use effectively in a hairy population in
a hot climate where people who are prone to perspire tend to
lose their patches (and receive ineffective dosing).
While pethidine has been used as though it were a step-three opioid [see Figure
5, page 43], it is only a step-two analgesic with weak efficacy. In addition, due
to the accumulation of its toxic metabolite, it is associated with a high risk of
serious adverse effects and is not appropriate for chronic pain management.
Innovation in Pain Management – Appendix 2
83
Appendix 2
Morphine: Optimal potential for benefit with a minimum risk
of adverse events and burden
Professor Jan Stjernswärd wrote: [12 April 2004]:
Cost effective
Both immediate and slow-release morphine preparations can be produced
generically at a cost similar to acetylsalicylic acid tablets (ASA/aspirin).185 In
contrast, more elaborate preparations, such as transdermal fentanyl186 may be
much more expensive for the same morphine-equivalent dose. In our
experience at WHO the relative cost of opioid preparations has been:
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186 N-Phenyl-N-(1-2-phenylethyl-4-piperidyl) propanamide (Duragesic patch, fentanyl transdermal
system, Janssen Pharmaceutica Products) was first synthesized in Belgium in the late 1950s and
marketed for injection as Sublimaze.
To control severe, chronic pain, use oral immediate and slow-release morphine
preparations that have optimal efficacy, minimal risk of adverse effects and
optimal cost-effectiveness. Parenteral morphine and other opioid formulations
[should] only [be used] when oral morphine preparations cannot be ingested
or in the few cases where they produce unacceptable adverse effects.
Drug
preparation name
relative cost
Morphine
oral immediate-release
(tablets and liquids)
1 x
oral slow-release
tablets
3 x
parenteral
5
Fentanyl
transdermal
20 or more
Oral immediate-release
morphine
30%
Oral slow-release
morphine
60%
Parenteral
morphine
5%
Other opioid
preparations
5%
Oral immediate-release morphine
Oral slow-release morphine
Parenteral morphine
10 and 20 mg tablets
5 and 20 mg/ml liquid
30, 60 and 100 mg tablets
2, 10 and 50 mg/ml injectable solution 
(preferably preservative-free)
WHO experience suggests that the following proportions are likely to be
needed to control chronic pain on a national scale:
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Professor Henry Knowles Beecher
(1904–76), anaesthestist at
Harvard University, observed
during his wartime service that
soldiers with serious wounds
complained of pain less often than
his post-operative patients at
Massachusetts General Hospital,
Boston. See www.library.ucla.edu/
biomed/his/painexhibit/panel5.htm
(visited 16 March 2004).
Professor Sir Michael Bond
Kt FRSE FRCS(Ed) FRCP(Glas)
FRCPsych DPM FRSA (b. 1936)
qualified from Sheffield University
in 1961 and was a lecturer in the
Department of Psychiatry there
from 1964 to 1967, and in the
department of neurosurgery at the
University of Glasgow from 1971
to 1973. He was appointed
Professor of Psychological
Medicine and Honorary
Consultant Psychiatrist, University
of Glasgow, from 1973 until 1998,
later Emeritus. He was President of
the International Association for
the Study of Pain in 2002–03. He
established the first psychologically/-
psychiatrically-based clinic and in-
patient Rehabilitation Unit for
Chronic Pain Patients in Glasgow
in 1982. With Issy Pilowsky, he
developed the Analogue Scale for
Pain Measurement in 1964. See
Bond and Pilowsky (1966).
Professor John Bonica
(1917–94), anaesthestist,
developed the use of the epidural
in childbirth. He became chief of
anaesthesiology at the Madigan
Army Hospital [WA] in 1944, later
founded the Multidisciplinary Pain
Centre at Tacoma General Hospital
[WA] in 1947, later at the
University of Washington in Seattle
from 1960, where he was head for
18 years. Arising from his work
with regional blocks to control
pain, and his wife’s complications
from ether anaesthesia, he devised
a system of continuous epidural
analgesia that permitted the control
of labour pain without the patient
losing consciousness. His two-
volume work, The Management of
Pain [Bonica (1953)], remains the
standard text on the subject. The
International Association for the
Study of Pain was founded under
Bonica’s leadership in 1973 and he
was its first President. 
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Sir Kenneth Calman 
KCB FRCP FRCS FRSE FMedSci
(b. 1941) has been Vice-
Chancellor and Warden of
Durham University since 1998. He
was lecturer in surgery at the
Western Infirmary, Glasgow, from
1968 to 1972; MRC Clinical
Research Fellow, London, from
1972 to 1973; Professor of
Oncology, Glasgow University,
from 1974 to 1984; Dean of
Postgraduate Medicine from 1984
to 1989; Chief Medical Officer,
Scottish Home and Health
Department from 1989 to 1991;
Chief Medical Officer at the
Department of Health from 1991
to 1998 and Chairman of the
World Health Organization
Executive Board from 1998 
to 1999.
Professor David Clark
PhD (b. 1953) was educated at 
the Universities of Newcastle-
upon-Tyne and Aberdeen. He was
appointed Professor of Sociology 
at Sheffield Hallam University 
in 1993 and in 1995 became
Professor of Medical Sociology 
at the University of Sheffield. 
He has been Professor of Medical
Sociology and Director 
of the International Observatory
on End of Life Care at Lancaster
University since September 2003.
Professor Marshall Devor
(b. 1949) is Professor and
Chairman of the Department 
of Cell and Animal Biology, Life
Sciences Institute, Hebrew
University, Jerusalem, Israel.
Dr Niki Ellis
is an occupational and public health
consultant in Sydney, Australia. 
She was a Research Fellow at the
Wellcome Trust Centre for the
History of Medicine at UCL 
from September 2002 to 2004.
Professor Hans Eysenck
PhD DSc (1916–97), a
psychologist, was raised by his
grandmother in Berlin, moving 
to London at 18. A student of Sir
Cyril Burt, he received his PhD 
in psychology from the University
of London in 1940. In 1946 
he founded the Psychology
Department at the Institute of
Psychiatry, University of London,
where he was head of department
from 1950 and Professor of
Psychology from 1955, until his
retirement in 1983, later Emeritus.
See www.pbarrett.net/
hans_eysenck.htm (visited 
16 March 2004).
Professor Sigmund Freud
MD (1856–1939), psychoanalyst,
was born in Moravia, later settled
in Vienna, where he studied
medicine. His research into the
Innovation in Pain Management – Biographical notes
104
clinical uses of cocaine was
conducted from 1884–87. He first
used the term ‘psychoanalysis’ in
1896. Among his many honours
was as a corresponding Fellow of
the Royal Society of London in
1936. After the Nazi invasion of
Austria in 1938, Freud and his
family moved to London where 
he died the following year. See
www.freudfile.org/coca.html 
and www.freud.org.uk/.(visited 
16 March 2004).
Professor Ralph Gerard
(1900–74), American physiologist,
had worked with A V Hill in
London and Otto Meyerhof in
Kiel on a National Research
Council Fellowship in 1926–27,
returning to the University of
Chicago Physiology Department 
in 1928, where he remained until
appointed Professor of
Neurophysiology and Physiology
in the College of Medicine,
University of Illinois, in 1952.
With Ling and Graham in 1949 
he introduced the intracellular
recording capillary microelectrode.
See also Libet (1974); Libet and
Reynolds (1974).
Sir George Godber
GBE FRCP HonFRCS
HonFRCGP HonFRCPsych
HonFRCOG (b. 1908) joined 
the Ministry of Health in 1939,
became Deputy to Sir John
Charles, the Chief Medical 
Officer, and succeeded him 
in 1960. He retired in 1973.
Dr Peter Hunter
MRCP (b. 1938) qualified from
Middlesex Hospital, London, in
1963 and was Consultant
Physician at the Royal Shrewsbury
Hospital, from 1974 to 1993.
From 1994 to 1997 he read
pharmacology at King’s College
London, as preparation for full-
time research on the history of
discovery of drugs and medicines
in the modern era.
Dr Jeremy Johnson
(b. 1950) developed an interest in
symptom control in patients with
advanced cancer, while training in
clinical oncology. A career change
to palliative medicine led him to
Shrewsbury where he has been
Medical Director of the Shropshire
and Mid Wales Hospice since 1989.
Mr David Joranson
(b. 1941) graduated from the
University of Wisconsin in 1970. 
He planned and administered a
comprehensive drug abuse treatment
programme at Madison, Wisconsin,
in 1972, designed and administered
a regulatory agency programme to
address diversion of controlled
substances in 1975; and was co-
founder of the Wisconsin Cancer
Pain Initiative and National
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Association of State Cancer Pain
Initiatives in 1986. He was
appointed Senior Scientist at the
University of Wisconsin and
established and has directed the Pain
and Policy Studies Group/WHO
Collaborating Center since 1996. 
Dr Leon Kaufman
FFARCS MAE (b. 1927) 
was Consultant Anaesthetist 
at University College Hospital,
London, from 1969 to 1989,
Honorary Senior Lecturer at
University College Hospital
Medical School, London, from
1969 to 2002, and at St Mark’s
Hospital, London, from 1965 
to 1991.
Dr Elisabeth Kübler-Ross
(1926–2004), American
psychiatrist and physician, born in
Zurich, trained in medicine after
being a hospital volunteer during
the Second World War. She moved
to the US shortly after marrying E
R Ross in 1958, specialized in
psychiatry and became assistant
professor at the University of
Chicago Medical School in 1965.
Her bestseller, Death and Dying
(1969), described five stages of
dying: denial, anger, bargaining,
depression and acceptance,
although not everyone experiences
all of them. See also Reed (2004).
Dr Suresh Kumar
(b. 1961), born in Kerala (India)
and qualified in anaesthesiology,
sociology and palliative medicine,
has been a Consultant in Palliative
Medicine at the WHO
Demonstration Project in Kerala
since 1997 and Director of the
Institute of Palliative Medicine,
Kerala, since 2002. He was 
part of the team that initiated
Neighbourhood Network in
Palliative Care (NNPC), the
community programme in Kerala
with massive grass roots-level
participation. 
Professor Louis Lasagna
(1923–2003) received his MD
from Columbia University in
1947. He started the first academic
group in clinical pharmacology 
at Johns Hopkins University. He
was Chairman and Professor of
Pharmacology and Toxicology and
of Medicine at the University of
Rochester School of Medicine and
Dentistry from 1970–80, and
Dean of the Sackler School of
Graduate Biomedical Sciences at
Tufts University, Boston, MA. 
Professor Henry McQuay
FRCA has been Professor of Pain
Relief at the University of Oxford
and Honorary Consultant, Pain
Relief Unit, Churchill Hospital,
Oxford. See McQuay and 
Moore (1998).
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Professor Chris Main
(b. 1947) was a clinical
psychologist with Salford Health
Authority from 1982 to 2002 
and in 1983 set up the first pain
management programme for low
back pain. He is co-author of Pain
management: An interdisciplinary
approach (Main and Spanswick,
2000). He has been Professor of
Clinical and Occupational
Rehabilitation at the University 
of Manchester since 2004 and
Visiting Professor in Primary 
Care Sciences at Keele University
since 2004.
Dr Marcia Meldrum
(b. 1949) received a Master’s
degree in Healthcare Management
from Boston University and
worked for ten years as a medical
administrator before beginning
graduate study in the history of
science and medicine, earning her
PhD from SUNY Stony Brook in
1994. She is currently Co-Director
of the John C Liebeskind History 
of Pain Collection at UCLA, where
she also lectures in the history
department. Her research interests
include the history of pain
management, of neuroscience, 
and of randomized clinical trials.
Professor Ronald Melzack
FRSC (b. 1929) received his PhD
from McGill University, Montreal,
Canada, in 1954, was appointed 
to Massachusetts Institute of
Technology, Boston, MA, USA,
where he met Patrick Wall, with
whom he proposed the gate control
theory for understanding the
mechanisms of pain. He returned
to McGill in 1963, and was E P
Taylor Professor of Psychiatry from
1986 until his retirement in 1999. 
He developed the McGill Pain
Questionnaire, (MPQ), the most
widely used measuring tool for
research on pain in human
subjects, and served as President of
the International Association for
the Study of Pain from 1984 to
1987. See Melzack and Wall
(1965); Melzack (1975). See also
www.science.ca/scientists/scientistp
rofile.php?pID=199 (visited 22 
June 2004).
Professor Harold Merskey
FRCP FRCPsych FRCPC 
(b. 1929) completed his DM thesis
(Oxford) in 1964 on pain in
psychological illness, while at 
the University of Sheffield under
Erwin Stengel, and was a Physician
in Psychological Medicine at the
National Hospital for Nervous
Diseases, Queen Square, London,
from 1967 to 1976. He was
appointed Director of Research at
the London Psychiatric Hospital 
in London, Ontario, Canada, 
from 1976 to 1994 and was
Professor of Psychiatry at the
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University of Western Ontario,
London, Canada, from 1977 to
1994, later Emeritus.
Professor Balfour Mount
OC OQ FRCSC (b. 1939) 
trained as an Urologist at McGill
University and as a Surgical
Oncologist at Memorial Sloan-
Kettering Cancer Center, New
York. His training in end-of-life
care was at St Christopher’s
Hospice, London, in 1973–74.
The following year he was
appointed Founding Director 
of the Royal Victoria Hospital
Palliative Care Service, part of the
McGill University Health Centre,
the Founding Director of the
Palliative Care Division of the
Department of Oncology at
McGill in 1991, and the first
holder of the Eric M Flanders
Chair in Palliative Medicine at
McGill in 1994.
Dr Peter Nathan
FRCP (1914–2002) qualified at
Middlesex Hospital in 1939. He
served as an army medical officer
and in 1941 was sent to Sir Hugh
Cairn’s head injuries unit in
Oxford, where the clinical aspects
of the work led to his interest in
understanding the neurological
aspects of pain, and the
investigation of new methods of
pain relief. He became a registrar 
at the National Hospital for
Nervous Diseases (later the
National Hospital for Neurology
and Neurosurgery) at Queen
Square, London, in 1946, later
Honorary Physician, and joined
the Medical Research Council
Neurological Research Unit there
in 1948, where he became involved
in research on the functioning of
the brain and spinal cord. He and
Pat Wall carried out the first UK
trial of transcutaneous electrical
nerve stimulation (TENS) for pain 
relief and tested the efficacy of
acupuncture for pain relief and
introduced its use into the NHS.
He was a founder member and the
first President of the British and
Irish chapter of the International
Association for the Study of Pain 
in 1979. His grandfather and
father started the company in New
Zealand that gave rise to the Glaxo
drug company. See Schott (2003).
Dr Alexander Nicholson
MBBS MRCGP (b. 1970)
qualified at the University of
Newcastle-upon-Tyne Medical
School in 1993 and has been
training as a Specialist Registrar 
in Palliative Medicine in the West
Midlands since 2001. 
Dr Colin Murray Parkes
OBE FRCPsych (b. 1928) was 
a member of the research staff at
the Tavistock Institute of Human
Relations from 1962 to 1975. He
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worked closely with Dame Cicely
Saunders as Consultant Psychiatrist
to St Christopher’s Hospice,
Sydenham, from its inception in
1967. Here he set up the first
hospice-based bereavement service
and carried out some of the earliest
systematic evaluations of hospice
care. He was a member of research
staff at Harvard Medical College
from 1965 to 1969 and Senior
Lecturer in Psychiatry at the 
Royal London Hospital Medical
College from 1975 to 1996. 
See Parkes (1975).
Professor Issy Pilowsky
FRCPsych, was Professor and Head
of the Department of Psychiatry at
the University of Adelaide and
Head of Psychiatric Sciences and
Consultant to pain clinics at the
Royal Adelaide Hospital, Adelaide,
Australia, until his retirement in
1998. He was a founder member 
of the Australian Society for
Psychiatric Research and has been a
Past Councillor of the
International Association for the
Study of Pain.
Mrs Jennifer Raiman 
(b. 1936) joined the Department
of Pharmacology and Therapeutics
at the Royal London Hospital and
Medical College in 1978 as a
Research Fellow undertaking a
study of protracted pain in patients
in the hospital and local
community. She developed the
London Hospital Pain Chart and
was seconded to Macmillan Cancer
Relief as Education Advisor in
1983, becoming Head of Medical
Services in 1986. She initiated and
developed Macmillan’s Medical
Services Programme in cancer and
palliative care. 
Professor Emery Rovenstine
(1895–1960) was a general
practitioner and a self-trained
anaesthetist in Indiana before
becoming an assistant to Dr Ralph
Waters in the Department of
Anaesthesia at the University of
Wisconsin. He was Professor and
head of the Department of
Anaesthesia at New York University
and Bellevue Hospital, New York,
in 1935, he formalized a science-
based approach to anaesthesia. See
Bacon (2002).
Dame Cicely Saunders
OBE DBE OM FRCP FRCS 
(b. 1918) founder and Medical
Director of St Christopher’s
Hospice, Sydenham, London, from
1967 to 1985 and Chairman from
1985 to 2000, first trained in
nursing, qualified, but back pain
barred practising. She returned to
St Anne’s, Oxford, gaining her
diploma in Public and Social
Administration and a war degree,
becoming a Lady Almoner at St
Thomas’ Hospital in 1947. She
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also was a volunteer sister at St
Luke’s, Bayswater, London, where
she learned to use analgesics at
regular intervals. She read
medicine, and trained at St
Thomas’s, qualifying in 1957. She
started as Halley Stewart Research
Fellow under Professor Harold
Stewart, St Mary’s Hospital
Medical School, London, working
at St Joseph’s Hospice, Hackney, in
1958 on pain in the terminally ill.
Her ‘scheme’ of 1959 was a
proposal for a 100-bed home for
those dying of cancer and other
diseases where pain could be
controlled and symptoms
alleviated, estimated to cost
£200 000. St Christopher’s was
established as a charity in 1961
with a council of management.
Funds accumulated, and the site in
Sydenham was blessed in 1963, the
foundation stone laid in 1965 and
St Christopher’s received its first
patients in 1967. She has also been
a member of the Medical Research
Council from 1976 to 1979 and
Honorary Consultant at St
Thomas’ Hospital since 1985. 
See du Boulay (1984).
Friedrich Wilhelm Sertürner
(1783–1841) first isolated
morphine from opium in 1805. 
He called it ‘morphium’ after
Morpheus, the Greek god of
dreams. See Huxtable and 
Schwarz (2001).
Professor Erwin Stengel 
(1902–73), Austrian–British
psychiatrist and psychologist, 
was Professor of Psychiatry at 
the University of Sheffield from
1957 to 1967. See www.whoname
dit.com/doctor.cfm/1492.html
(visited 19 January 2004).
Professor Harold Stewart
CBE DL FRCP FRSE
(1906–2001) qualified at
Cambridge and was in general
practice in Barnet, Hertfordshire.
Following his wartime activities, he
became a consultant in
pharmacology at 
St Mary’s Hospital Medical School,
London, in 1946 where he
remained, as Reader in 1949, Head
of the Pharmacology Department 
in 1950, Professor in the
University of London in 1965
until his retirement in 1974, later
Emeritus. His research was mainly
on human fat absorption and
transport and on problems of pain
and analgesia. See Wood-Smith
and Stewart (1962).
Professor Jan Stjernswärd 
PhD FRCP(Edin) (b. 1936) joined
the World Health Organization in
1980. He pioneered the global
development of pain relief and
palliative care through a rational
public health approach. As Chief 
of Cancer at WHO from 1980 to
1996 he initiated the ‘WHO
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Three-Step Pain Ladder’ developed
by a small team of specialists
(WHO (1986)), produced
manuals, policy guidelines for
palliative care and cancer control,
for National Cancer Control
Programme and Palliative Care
Programme and reoriented the
WHO Global Cancer Control to
an action programme for
implementing the accumulated
knowledge in cancer control.
Dr Mark Swerdlow
FFARCS DA (1918–2003)
developed his interest in the
problems of pain control as a
Consultant Anaesthetist in Salford
Royal Hospital from 1951 to
1980. He established one of the
first pain relief clinics in Britain,
the North West Regional Pain
Relief Centre, in 1959; founded
the Intractable Pain Society of
Great Britain (later the Pain
Society) in 1967, was elected
Chairman in 1971 and later
became an Honorary Member.
Following his retirement he
launched a new cancer pain relief
programme for WHO, where he
and a small group of specialists
developed the WHO analgesic
ladder method for treatment of
cancer pain, first published in 
1986. See Swerdlow (1974–89).
Dr Robert Twycross
FRCP (b. 1941) graduated from
Oxford University Medical School
in 1965 and was appointed
Research Fellow in Therapeutics at
St Christopher’s Hospice, London,
in 1971. He returned to Oxford in
1976 as Medical Director of Sir
Michael Sobell House, a palliative
care unit at the Churchill Hospital.
He was Macmillan Clinical Reader
in Palliative Medicine, Oxford
University, from 1988 until his
retirement in 2001. He has been
Emeritus Clinical Reader in Palliative
Medicine since 2001 and Academic
Director of the Oxford International
Centre for Palliative Care and Head
of the WHO Collaborating Centre
for Palliative Care.
Professor Duncan Vere
FRCP (b. 1929) was Consultant
Physician at the Royal London
Hospital from 1965 to 1995 and
Professor of Therapeutics in
London University at the London
Hospital Medical College, later
Emeritus. He was also chair of  
the Research Committee at St
Christopher’s Hospice, London.
Professor Gordon Waddell
FRCS has been Professor of
Orthopaedic Surgery at the
University of Glasgow, Consultant
at the Glasgow Nuffield Hospital,
visiting Professor at the
rheumatology department of the
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University of Manchester, and
Associate Professor of Clinical
Research at the British School of
Osteopathy, London, since 1996.
Professor John Walker-Smith
FRCP FRACP FRCPCH (b. 1936)
was appointed Consultant/Senior
Lecturer in Child Health at St
Bartholomew’s and Queen Elizabeth
Hospital for Children in 1973, and
became Professor of Paediatric
Gastroenterology in 1985. He
transferred to the Royal Free
Hospital, London, in 1995, retiring
in 2000, later Emeritus. He spent a
sabbatical in history of medicine at
the Wellcome Institute for the
History of Medicine, now the
Wellcome Trust Centre, in 1993,
returning as Research Associate in
the History of Medicine in 2000,
and has been a member of the
History of Twentieth Century
Medicine Group since 1993.
Professor Patrick Wall
DM FRS (1925–2001) qualified 
in medicine at the University of
Oxford during the Second World
War, chose research as a career and
worked at physiology laboratories 
at Yale, Chicago, Harvard and 
MIT until appointed Professor 
of Anatomy and Director of the
MRC Cerebral Functions Group 
at University College London in
1967, where he remained until his
retirement in 1992. He developed
the gate control theory of pain
with the Canadian psychologist
Ron Melzack, which moved the
focus of theories of pain to the
spinal cord. With Sweet he also
developed the transcutaneous
electrical nerve stimulator (TENS)
for pain. He was a founding
member of the Brain Research
Association (later British
Neuroscience Association), the
International Association for the
Study of Pain and founding editor
of the journal Pain, as well as joint
editor with Melzack of the
successful Textbook of Pain. See
Melzack and Wall (1965); Wall
and Melzack (1999); Wall and
Sweet (1967) and appreciations 
of his career in the British
Neuroscience Association
Newsletter 40 (2001): 1–3. 
Dr Martin Wright
FRCP (1912–2001), the inventor
of the continuous infusion pump
now universally used in terminal
and postoperative care, was a
bioengineer who joined the
Medical Research Council
Pneumoconiosis Research Unit at
Llandough Hospital, Penarth,
South Glamorgan, in 1949. He
moved to the National Institute for
Medical Research, Mill Hill,
London, in 1957 to work solely on
instrument development, then to
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the MRC’s Clinical Research
Centre at Northwick Park
Hospital, Harrow, in 1969 until
his retirement. Among other
equipment, he developed the
Wright respirometer, an infant
apnoea monitor and the standard
breath alcohol detector. The MRC
holds the patents on all his
inventions. See Wright (2001);
Davenport (1998).
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acetylsalicylic acid (ASA; aspirin), 39, 84
acute pain, 14
addiction, 70
absence of, 7, 8, 9
fear of, 49, 54
adjuvant analgesics, 24, 25
Africa, 40, 44, 47–48, 52, 57
AIDS, 47, 58, 66
alcohol injections, 9–10
American Alliance of Cancer Pain
Initiatives, 50
American Cancer Society, 63
American Pain Society, 71
amitriptyline, 22, 23, 24, 31
see also tricyclic antidepressants
anaesthetists, 10, 14, 81, 82
analgesia see pain control
analgesic drugs, 5, 67
adjuvant, 24, 25
affordability, 57–58, 69–70
availability, 21, 44–54, 56–59
concepts of use, 15–16
cumulation, 16
gender-specific prescribing, 21
mixtures see Brompton cocktail
non-narcotic, 5
unethical marketing, 47–48, 58–59,
69–70
WHO three-step ladder, 41, 42–44,
50, 69
see also opioid analgesics; specific agents
analogue scale, pain, 21
animal studies, 37, 38
antidepressants see tricyclic
antidepressants
antiemetics, 24
antiepileptic drugs (anticonvulsants),
23, 24, 25, 30–31
anxiolytic drugs, 24
aspirin, 39, 84
Australia, 34, 68–69
autonomic nervous system, 73–74
back pain, 14, 31–34
Bandaranaike Memorial Home, 
Sri Lanka, 63
Bat-Sheva Seminar on Pain
Mechanisms and Therapy,
Jerusalem, 4
behaviour therapy, 4–5, 12, 13, 68
Bell Telephones, 76
bereavement, 61
biopsychosocial model, 32, 34, 68
body outlines, 18–20, 36–37
Brain, 79
The Brain of the Tiger Salamander
(Herrick), 82
breakthrough pain, 15
British Medical Journal, 9, 27
British National Formulary (BNF ), 27–28
Brompton Chest Hospital, London, 27
Brompton cocktail (Mist. Obliterans),
6, 15, 26–29
Bulgaria, 58–59
burial, 61
Burkitt’s lymphoma, 40
‘calculating women’, 75
Calicut Declaration, 46
Calicut WHO Demonstration Project,
India, 46, 47, 52
Canada, 31, 44–45
cancer pain, 11, 12, 18, 27, 66
adjuvant drugs, 24
intrathecal diamorphine, 35–36
psychological aspects, 34–35
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cancer, pain (cont’d.)
training in management, 20–21
WHO initiatives, 39–54
Cancer Pain Relief (book; WHO
1996), 45
Cancer Pain Relief (journal), 46
carbamazepine (Tegretol), 24, 30–31
Cardiff, 20, 21, 22
Catalonia WHO Demonstration
Project, Spain, 46–47
Centre Soins Continue, Geneva, 42–43
Chicago, University of, 75
China, 52
chlorpromazine, 24, 28
Christianity, 15, 59–60, 61
chronic pain (syndrome), 8, 14
disability, 65
opioid analgesics, 50, 83, 84
psychological aspects, 13, 32, 33, 68
see also intractable pain
Cipla Pharmaceuticals, India, 58
circumcision, 68–69
Citation Classic, 81
City of London Migraine Clinic, 70
Clinical Standards Advisory Group
(CSAG), 64–65
clinical trials, 7–9, 16–17, 28, 29
cocaine, 9, 15, 27, 28–29, 30, 35
cognitive behavioural therapy, 12, 68
Controlled Substances Board,
Wisconsin, 48–49
cortical stimulation studies, 73–74
corticosteroids, 24
cultural differences, 60–62, 63
Cybernetics (Wiener), 75
Department of Health, 13
Department of Health and Social
Security (DHSS), 8, 29
depression, 13
developed countries, 39, 52
developing countries, 39, 41, 48
dexamphetamine, 29
diamorphine (diacetyl morphine;
heroin), 16, 27
availability, 48–49
in Brompton cocktail, 28–29
continuous treatment, 64
intrathecal, 35–36
vs morphine, 8–9, 16, 28, 29
diazepam, 24
Dicey’s law, 59
disability, 32, 65
dorsal horn, 78, 80
Drug Directorate, Canadian
Department of Health and Welfare, 
44–45
dying patients, care of see palliative care
education/training
development in UK, 20–21
in India, 46, 55, 56, 58
shortcomings, 26, 41
WHO initiatives, 44, 46, 49
end-of-life pain, 5–6, 7, 66–67
see also palliative care
Eysenck personality construct, 12
Fellowship of the Royal College of
Anaesthetists (FRCA), 82
fentanyl, transdermal (patches), 48, 
69, 83, 84
Floriana Foundation, Milan, Italy, 42
Florinapolis Declaration, 46
gate control theory of pain, 23, 37, 68, 
78–81
diagram, 79, 80
gender differences, analgesic
prescribing, 21
general practice, 15, 20–21
Germany, 43, 59
gin, 15
Glasgow Illness Model, 32
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Green Paper, vocational rehabilitation,
34
Gwálior Hospital, India, 58
haloperidol, 24, 29
health care professionals
attitudes to pain, 18, 21–22
education/training of see
education/training
herbal remedies, 39
heroin see diamorphine
home-centred care, 17, 29, 55
Hospice in Asia Conference,
Singapore, 54
hospice movement, 18, 21
hospices, 8, 66
effectiveness of pain control, 17–18
pain control principles, 15, 29
use of nerve blocks, 11
hospitals, general, 15, 17, 18, 21–22
hydroxyzine, 24
hypochondriasis, 12
hysteria, 12
IASP see International Association for
the Study of Pain
Illness Behaviour Questionnaire, 12
INCB see International Narcotics
Control Board
India, 47, 52–58
morphine availability, 45, 51, 52–54,
56-58
palliative care, 46, 55–56, 58
see also Kerala, India
Indian Association of Palliative Care, 58
information theory, 76
interdisciplinary approach see
multidisciplinary (team) approach
International Association for the Study
of Pain (IASP), 10–11
definition of pain, 13
foundation, 3, 4, 82
International Narcotics Control Board
(INCB), 45, 50, 52, 54
International Physiological Congress,
Montreal (1953), 76–77
intractable pain, 18, 21, 23–24
see also cancer pain; chronic pain
Intractable Pain Society see Pain Society
IRM see morphine, immediate-release
Israel, 4
Issaquah, Seattle, Washington, 4
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